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 Abstract 
 
 It is a cause for significant concern that, as the threat of multi-drug resistant 
strains of bacteria has increased, the discovery of effective and novel antibiotics has 
stalled. The bacteriocin class of antimicrobial peptides have, in recent times, 
emerged as a viable alternative to at least partially fill the void created by the end of 
golden age of antibiotic discovery. Along with this potential use in a clinical setting, 
a number of bacteriocins also play an important role as bio-preservatives in the food 
industry. 
This thesis focuses on a specific group of the bacteriocins, the Class 1 
lantibiotics (Lanthionine-containing antibiotics). The mature peptide structure 
contains a number of unique amino acids which result from enzymatically mediated 
post-translational modifications, including dehydration and cyclisation, leading to 
the formation of the eponymous (methyl)lanthionine bridges. Two characteristics 
associated with lantibiotics are exploited in this work. Firstly, the many ways in 
which they can be applied in a food setting, and secondly, how their gene-encoded 
nature can be modified to improve on overall bioactivity and functionality.  
The research focuses on two lantibiotics, lacticin 3147 and nisin A, both of 
which are produced by strains of Lactococcus lactis. The use of a lacticin 3147 
producing starter culture with a view to the control of the Crohn’s disease-linked 
pathogen Mycobacterium avium subspecies paratuberculosis was assessed in a 
smear ripened raw milk cheese. The fact that bacteriocin production did not 
effectively control the pathogen was one of a number of factors that provided an 
impetus to explore a variety of PCR-based mutagenesis techniques with a view to the 
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creation of enhanced lantibiotic derivatives. Initially there was a specific focus on 
the three amino acid central ‘hinge’ region of nisin A, chosen because previous 
bioengineering of this region led to variants with enhanced properties.  
Through the use of both site specific and site directed mutagenesis 
techniques, a number of enhanced derivatives were generated. A derivative in which 
the three hinge amino acids (asparagine, methionine and lysine) were replaced with 
three alanines represents the first enhanced derivative of nisin to have been designed 
through a rational process. This derivative, named nisin AAA, also formed the 
backbone for the creation of an active, trypsin resistant, nisin variant. This stemmed 
from the observation that the lysine at position 12 provided the only trypsin sensitive 
peptide bond in nisin AAA. Introduction of a methionine residue at this position led 
to the creation of nisin K12M-AAA, which maintained antimicrobial activity while 
demonstrating resistance to the protease. This functional change could see nisin used 
as an oral anti-bacterial in the future as this derivative is more likely to be capable of 
withstanding gastric transit. A number of lead nisin derivatives were investigated to 
assess their anti- Streptococcus agalactiae ability. The ability of the AAA producer 
to control this target, which can contribute to the commercially important disease, 
bovine mastitis, was evident from these studies. Finally, a system was also 
developed to facilitate the large scale production of these candidates, or other nisin 
derivatives, from dairy substrates with a view to anti-mastitis or other therapeutic 
preparations. 
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Chapter I 
Literature Review 
Lantibiotic-related research and the application 
thereof 
 
 
Brian Healy, Jim O’Mahony, Colin Hill, Paul D. Cotter and R. Paul Ross. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was published in Antimicrobial peptides: discovery, design and novel 
therapeutic strategies 18 (2010): 22-39. 
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1.1 Abstract 
 
Since the discovery, in 1925, that strains of E. coli can retard the growth of 
neighbouring bacteria, the study of bacteriocins has evolved continuously. During 
the intervening period a large and heterogeneous, collection of these antimicrobial 
peptides has been isolated from a myriad of sources and numerous investigations 
have been carried with a view to harnessing this potency. The most thoroughly 
investigated class of bacteriocins, the lantibiotics, will be the main focus of this 
review. These antimicrobial peptides inhibit many human and animal pathogens and 
have been the focus of considerable efforts to maximise the potential of existing 
lantibiotics, identify new and better lantibiotics from nature and to utilise 
bioengineering-based approaches to further improve upon existing well characterised 
compounds. 
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1.2 Introduction to Bacteriocins  
 
In order for an organism to survive, thrive and proliferate in a particular 
niche, it is essential that it competes successfully. In the microbial world many 
bacteria gain an upper hand by producing antimicrobial compounds which inhibit 
their competitors. Bacteriocins, which are bacterially-produced ribosomally-
synthesized peptides with antimicrobial spectra which can range from very narrow to 
extremely broad, can be among the most potent examples of bacterially produced 
antimicrobials (Tagg et al., 1976, Jack et al., 1995, Riley & Wertz, 2002, Cotter et 
al., 2005). Indeed, bacteriocins frequently exhibit antimicrobial activity at nanomolar 
levels which contrasts with, for example, the cationic antimicrobial peptides 
(CAMPs) produced by eukaryotic cells which only exhibit similar levels of activity 
at micromolar concentrations (Nissen-Meyer et al., 2009).  
The identification of the first bacteriocin, a colicin (i.e. an Escherichia coli-
associated bacteriocin (Gratia, 1925)), occurred in 1925. This was followed soon 
after by the first report of a bacteriocin produced by a Gram-positive bacterium when 
inhibition of a Lactobacillus bulgaricus by a Streptococcus lactis (since renamed 
Lactococcus lactis) was noted (Rogers, 1928). Since then, bacteriocins produced by 
lactococci and other lactic acid bacteria (LAB), i.e. microorganisms which have a 
long history of safe use in food and are of considerable industrial importance, have 
continued to be the focus of much attention (Nissen-Meyer et al., 2009). There are a 
number of different classification systems for LAB bacteriocins but the simplest, and 
that used for this review, was proposed by Cotter et al, (Cotter et al., 2005) and 
comprises two classes i.e. Class I bacteriocins: the post-translationally modified 
lantibiotics (Chatterjee et al., 2005, Cotter et al., 2005), and  Class II bacteriocins, 
which are a heterogeneous group of non lanthionine-containing peptides. As a 
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consequence of their unusual structure, unique mechanisms of action and their 
potential as antimicrobials for food, veterinary and clinical application, the 
lantibiotics have been the targetof much attention in recent years and are the focus of 
this chapter.  
 
1.3 Biosynthesis and Post-Translational Modifications 
 
The name lantibiotics is derived from lanthionine-containing antibiotics and 
reflects the feature which is shared by all of these peptides i.e. intra-molecular rings 
formed by the thioether amino acids lanthionine (Lan) and methylanthionine 
(meLan) (Sahl et al., 1995). Lantibiotic-associated gene clusters can be located on 
chromosomes (including transposable elements) or plasmids and in addition to the 
genes encoding a structural peptide(s) and the post-translational modification 
machinery that acts thereon, other genes responsible for regulation, transport and 
immunity are usually also present (Cotter et al., 2005). Here the steps involved in 
lantibiotic biosynthesis are summarized. 
 The lantibiotic prepropeptide contains a leader region which is eventually 
cleaved generating propeptide which is modified to become the active antimicrobial. 
The corresponding gene is generically designated lanA. Lantibiotics can be further 
subdivided according to the enzymes which catalyse (me)Lan formation. Type I 
prepropeptides such as the prototypic lantibiotic, nisin A, undergoes dehydration as a 
result of the catalytic activity of the NisB protein (generically referred to as LanB 
enzymes) (Karakas Sen et al., 1999). As a result specific serine and threonine 
residues are dehydrated to become the unique amino acids 2,3-dehydroalanine (Dha) 
and 2,3-dehydrobutyrine (Dhb), respectively. Some or all of these new residues are 
7 
 
then the subject of a LanC catalysed reaction which results in their interaction with 
the thiol groups of cysteines within the peptide to form Lan and meLan, from Dha 
and Dhb, respectively. Insight into the role of LanC was first provided by Meyer and 
co-workers (Meyer et al., 1995) who, while working on the lantibiotic Pep5, showed 
that with the removal of the pepC gene, the peptide produced contained dehydrated 
residues but not lanthionine or methlyllanthionine bridges. In addition to being 
essential for converting the peptide to an active form, the (me)Lan structures are also 
believed to contribute to protease resistance (Kluskens et al., 2005). Unlike the Type 
I peptides which are modified by two separate modification enzymes, Type II 
peptides, such as lacticin 481 and mersacidin, are modified by a single protein 
referred to as LanM (Willey and van der Donk, 2007). Another variation on this 
theme arises as a consequence of the existence of two peptide lantibiotics, such as 
lacticin 3147, which require the combined activity of two (me)Lan-containing 
peptides for optimal activity. In the majority of cases the production of lantibiotics of 
this kind relies on the presence of two LanM proteins, each of which are responsible 
for the dehydration and cyclisation of their respective subunit (McAuliffe et al., 
2000, Lawton et al., 2007). A third category of peptides, Type III, isnot described in 
this review as those identified to date, while possessing (me)Lan structures, lack 
antimicrobial activity (Willey & van der Donk, 2007) while yet another category, 
modified by a novel group of lantibiotic synthetases designated LanL, has recently 
been discovered (Goto et al., 2010). It  remains to be established if LanL modified 
peptides possess antimicrobial activity and thus it has been suggested that the term 
lantipeptides be used to describe lanthionine-containing peptides that lack 
antimicrobial activity (Goto et al., 2010). With respect to the lantibiotics, in addition 
to the LanB, C and M enzymes, a number of other modification enzymes have been 
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associated with the modification of specific peptides (Kupke & Gotz, 1997, Peschel 
et al., 1997, Majer et al., 2002, Cotter et al., 2005). 
After modification, the peptide is transported via an ABC transport system to 
the cell surface (Fath & Kolter, 1993) and the leader sequence is proteolytically 
removed, although  not necessarily in that order, leading to the production of the 
active lantibiotic (Havarstein et al., 1995). For Type I lantibiotics these individual 
steps are carried out independently by a transporter (designated LanT) (Qiao and 
Saris, 1996) and a protease (LanP)(Ye et al., 1995, Siezen, 1996), whereas in the 
case of Type II lantibiotics both activities are carried out by one enzyme (also 
designated LanT) (Rince et al., 1994, Chen et al., 1999, Altena et al., 2000). To 
ensure that the active antimicrobial does not target the producing cells, immunity 
proteins are produced. Two immunity mechanisms have been described. One relies 
on a single immunity protein, LanI, while a second involves a multi-component 
ABC-transporter system referred to as LanEFG. Indeed some lantibiotic producers 
utilize two such mechanisms (Draper et al., 2008). The remaining group of 
lantibiotic-associated proteins to which we have yet to refer are the regulators. Initial 
studies in this area focused on the regulation of nisin, and its related peptide, subtilin 
by two component signal transduction systems which consist of a histidine kinase 
(LanK) and a response regulator (LanR) (Klein et al., 1993, Engelke et al., 1994, 
Stock et al., 2000, Kleerebezem, 2004). Examination of the genetic determinants of a 
subtilin producer revealed the presence of the spaK and spaR genes. Using a strategy 
of gene deletion, it was shown that mutants lacking these genes were no longer 
capable of lantibiotic production (Klein et al., 1993). A similar approach also 
revealed the importance of the corresponding nisin genes (Engelke et al., 1994). In 
both cases, it has been established that the associated antimicrobial peptides also 
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function as pheromones as part of a LanRK-mediated quorum sensing system which 
facilitates autoregulation (Kleerebezem, 2004). While two component systems play a 
major role in the production of a number of other lantibiotics, such as mersacidin 
(Guder et al., 2002), other quite different regulators have also been noted (McAuliffe 
et al., 2001).  
 
1.4 Classification 
 
A scheme to classify lantibiotics was first proposed by Jung in 1991 (Jung, 
1991). This scheme grouped the peptides into two distinct categories. The first class, 
Type-A, contained the elongated flexible, amphipathic, peptides. These peptides also 
had an overall positive net charge and were thought to function through the 
permeablization of the cell membrane. The second class, Type-B, were grouped on 
the basis of being globular proteins, with a net negative or neutral charge and were 
thought to function by inhibiting sensitive cells by forming complexes with specific 
membrane components. While some of this information continues to be pertinent, 
investigations which have established that some lantibiotics act in multiple different 
ways, coupled with the identification of new and more diverse lantibiotics, makes the 
use of this system more difficult. This issue has been addressed by approaches that 
reflect the genes and proteins involved in lantibiotic production. Most recently this 
has involved the fusion of two compatible approaches (Piper et al., 2009a) in which 
peptides were classified on the basis of the sequence of the lantibiotic propeptide 
(Cotter et al., 2005) or the composition of the associated modification/ transport 
systems (Pag & Sahl, 2002, Willey & van der Donk, 2007). Using this combined 
approach the lantibiotics can be subdivided into the three types, i.e. I, II and III, 
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referred to above, and 12 subgroups. The subclassification of the type I and II 
lantibiotics into 12 subgroups is based on the alignment of the unmodified amino 
acid sequence of the structural peptide. In each case homology results in the 
classification of the lantibiotic in question together with the eponymous member of 
the group i.e. planosporicin, nisin, epidermin, streptin, Pep5, lacticin 481, 
mersacidin, ltnA2, cytolysin, lactosin S, cinnamycin and sublancin (Fig. 1.1). Thus, 
for example, the mersacidin subgroup includes RumB, plantaricin C, mersacidin, 
michiganin, actagardine, C55a, LtnA1, SmbB, bhtA-alpha, Plwa, PmnA1 and 
BhaA1, all  of which are modified by LanM enzymes (i.e. are of Type II) and 
contain a number of residues that are conserved across the group. It should be noted 
that problems can arise when trying to add newly purified lantibiotics for which a 
structure, but not gene sequences, are available to this system. Thus, while it is 
apparent from its unusual structure and modifications that microbisporicin represents 
a 13
th
 lantibiotic subclass (Castiglione et al., 2008), it will not be possible to 
satisfactorily incorporate it into the system until the associated biosynthetic genes are 
identified and the lanA gene sequenced.  
 
1.5 Lantibiotic subgroups – Biology, Structure and Mode 
of Action 
1.5.1 Nisin-like lantibiotics  
 
Nisin A is the most thoroughly characterized lantibiotic. This 34 amino acid 
peptide contains three dehydrated amino acids and five thioether rings (Fig 1.2) 
(Gross & Morell, 1971, Buchman et al., 1988) and is the eponymous member of the 
nisin-like lantibiotics, which also include nisin Z (Mulders et al., 1991), nisin F (de 
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Kwaadsteniet, et al., 2008), nisin U and U2 (Wirawan et al., 2006), nisin Q (Zendo 
et al., 2003), subtilin (Klein et al., 1993), ericin S and ericin A (Stein et al., 2002). 
The mechanism of action of nisin A (and nisin Z, which differs from nisin A by one 
amino acid) has been investigated in depth and it is likely that all related peptides 
function in a broadly similar manner. In addition to a long standing appreciation of 
its ability to form pores, it was revealed in the mid-90s that nisin binds to lipid II, an 
essential precursor of peptidoglycan and thus also inhibits cell wall synthesis (Brotz 
et al., 1998, Breukink et al., 1999). Structural analysis of the lipid II-nisin complex 
has revealed that the N-terminal region of the nisin peptide is responsible for lipid II 
binding (Hsu et al., 2004). The C-terminal end of the peptide, which is linked to the 
N-terminus by a three amino acid ‘hinge’ region, is the pore-forming domain 
(Breukink et al., 1997, Wiedemann et al., 2001). The efficiency of pore formation is 
greatly enhanced by lipid II-binding (Breukink et al., 1999). A third mode of action 
has also been revealed in that it is now apparent that nisin can induce the autolysis of 
susceptible staphylococcal strains as a consequence of the release of two cell wall 
hydrolyzing cationic enzymes during normal autolysis of dividing cells (Hasper et 
al., 2004).  
1.5.2 Epidermin-like lantibiotics 
 
Epidermin is produced by Staphylococcus epidermidis and is encoded by a 
structural gene, epiA, which is located on a 54 kb plasmid (Schnell et al., 1992). The 
active lantibiotic is a 21 amino acid peptide which contains four rings including three 
(me)Lans and a 2-aminovinyl-D-cysteine (Allgaier et al., 1986). After epidermin, 
gallidermin is the most extensively studied epidermin-like lantibiotic. The two 
peptides are structural analogues which differ by only one residue (at position 
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6)(Kellner et al., 1988). NMR studies into the structure of gallidermin has revealed 
that the rigid N-terminally located rings A and B are connected to the C and D rings 
at the C-terminal end of the peptide by a somewhat flexible region spanning residues 
A12 to G15 (Ottenwalder et al., 1995). A comparison of the structures of epidermin 
and nisin show a high homology in the N-terminal, lipid II-binding, ends of the 
peptides (Hsu et al., 2004) whereas their C-terminal ends differ considerably, 
thereby explaining the inability of epidermin to form pores in certain targets (Bonelli 
et al., 2006).  
1.5.3 Planosporicin- and Streptin-like lantibiotics 
 
In addition, to the nisin- and epidermin-like peptides, there exist two other 
peptides, planosporicin and streptin, which resemble the former with respect to their 
N-terminal domains but differ quite considerably from these, and from one another, 
otherwise. As a result both are the eponymous (and sole) members of two lantibiotic 
sub-classes. Planosporicin, produced by Planomonospora sp., contains both Lan and 
meLan residues which generate five intramolecular thioether bridges (Fig 1.2) 
(Castiglione et al., 2007, Maffioli et al., 2009). Planosporocin functions primarily 
through the inhibition of peptidoglycan synthesis but unlike nisin and epidermin 
does not bind to the D-ala-D-ala motif of lipid II (Castiglione et al., 2007). Streptin 
is a Streptococcus pyogenes-associated lantibiotic, two major forms of which have 
been purified. Streptin 1 is the fully mature 23 amino acid peptide while a second 
form, streptin 2 has three additional residues at the N-terminal end (TPY)(Karaya et 
al., 2001, Wescombe & Tagg, 2003).  
1.5.4 Pep5-like peptides 
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Pep5 is a tricyclic lantibiotic consisting of 34 amino acids (including 3 
lanthionine bridges; one meLan and two Lan)(Bierbaum et al., 1994, Bierbaum et 
al., 1996) and is both screw shaped and highly cationic, the latter being due to the 
presence of six lysine and two arginine residues in the mature peptide (Pag et al., 
1999). It is produced by Staphylococcus epidermidis strain 5 (Kaletta et al., 1989) 
with the associated genes being located on the 20 kb plasmid pED503 (Ersfeld-
Dressen et al., 1984, Meyer et al., 1995). Pep5 also has another less common feature 
i.e. an N-terminal 2-oxobutyryl group which is thought to be formed through the 
non-enzymatic hydrolysis of N-terminal Dhb residues (Xie & van der Donk, 2004). 
Pep 5 exerts its mode of action by forming voltage dependant pores in the 
cytoplasmic membrane of sensitive cells (Sahl et al., 1987, Kordel et al., 1989). 
These pores then cause the leakage of essential metabolites and ATP out of the cell 
resulting in the cessation of cellular metabolic processes and ultimately causing cell 
death. Pep5 can also induce the autolysis of staphylococci through the activation of 
cell wall hydrolysing enzymes (Bierbaum & Sahl, 1985, Bierbaum & Sahl, 1987).   
1.5.5 Lacticin 481-like lantibiotics 
 
The Type II lacticin 481-like subgroup is the largest lantibiotic subgroup and 
the associated peptides are also notable by virtue of lacking post-translational 
modifications other than the common Dha, Dhb, Lan and meLan residues (Dufour et 
al., 2007). The Lactococcus lactis ssp. lactis CNRZ481-produced eponymous 
member of this group, lacticin 481, is 27 amino acids in length and contains two 
Lans, one meLan and one Dhb residue (Fig 1.2)(Piard et al., 1993, van den Hooven 
et al., 1996). Interestingly, although lacticin 481 is quite similar to the related 
variacin (five amino acid differences), variacin appears to have a much broader 
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target-cell spectrum of activity (Pridmore et al., 1996). Studies with another member 
of this group, nukacin ISK-1, indicate it to be bacteriostatic and incapable of pore 
formation (Asaduzzaman et al., 2009) whereas the related streptococcin SA-FF2 
peptide causes the formation of short-lived pores in target cells (Jack et al., 1994). 
1.5.6 Mersacidin-like lantibiotics 
 
Mersacidin is a small lantibiotic produced by Bacillus spp. (Chatterjee et al., 
1992). The biosynthetic gene cluster (12.3 kb in size) consists of 10 genes and is 
located on the bacterial chromosome. This hydrophobic and neutral peptide contains 
three meLans and a single 2-aminovinyl-2-methylcysteine corresponding to four 
intramolecular rings (Fig 1.2)(Chatterjee et al., 1992). Mersacidin does not form 
pores in the cell membrane of sensitive cells but does inhibit cell wall synthesis 
through binding with lipid II (Brotz et al., 1995). An NMR study carried out by Hsu 
and co-workers showed that mersacidin can change its conformation depending 
whether or not it is in the presence of lipid II (Hsu et al., 2003). In addition to one 
peptide lantibiotics such as mersacidin, the mersacidin-like peptides also contain the 
A1 peptide of a number of two peptide lantibiotics i.e. lacticin 3147 (Fig 1.2)(Ryan 
et al., 1999), staphylococcin C55 (Navaratna et al., 1998), plantaricin W (Holo et al., 
2001), BHT (Hyink et al., 2005), Smb (Yonezawa & Kuramitsu, 2005), licheniciden 
(Begley et al., 2009, Dischinger et al., 2009) and haloduricin (Fig 1.2)(Mc Clerren et 
al., 2006, Lawton et al., 2007). These two peptide lantibiotics only exhibit optimal 
activity when the A1 component is combined with its A2 counterpart. These 
conserved A2 peptides are referred to as the LtnA2-like peptides and are described 
below.  
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1.5.7 LtnA2-like peptides  
 
Lacticin 3147 is the most extensively studied two peptide lantibiotic and is 
produced by Lactococcus lactis subsp. lactis DPC3147 (Ryan et al., 1996). The 
genes responsible for the production of the lantibiotic, and of the associated 
immunity proteins, are encoded on a 60.2 kb conjugative plasmid, pMRC01, which 
contains 10 ORFs (Dougherty et al., 1998). The mechanism of action of lacticin 
3147, which is also lipid II mediated, depends on the presence of both components 
i.e. Ltnα and β (derived from the LtnA1 and LtnA2 propeptides, respectively). More 
specifically, Ltnα first binds to lipid II in sensitive cells. This binding is thought to 
lead to a conformational change which produces a high affinity binding site for the 
Ltnβ peptide. Cell death occurs through the permeabilization of the cell membrane 
(Wiedemann et al., 2006) leading to the efflux of K
+
 ions and phosphate resulting in 
hydrolysis of cellular ATP. The related haloduracin peptide has recently been shown 
to function in a similar way (Oman and van der Donk, 2009)  
1.5.8 Other Type II Lantibiotics  
 
Other type II subgroups include the cinnamycin-like, sublancin-like, lactocin 
S-like and cytolysin-like subgroups. While there are a number of cinnmaycin-like 
peptides, sublancin, lactocin S and cytolysin are the sole members of their respective 
subgroups. Cinnamycin is a tetracyclic lantibiotic produced by Streptoverticillium 
grisoverticillutum. It is a 19 amino acid peptide and contains the unusual residues 
lysinoalanine and 3-hydroxyaspartic acid (Fig 1.2). In addition to its antimicrobial 
activity, cinnamycin and related peptides have other potentially useful 
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pharmaceutical properties, including the inhibition of phospholipase A2 and 
angiotensin converting enzyme (Fredenhagen et al., 1990, Kaletta et al., 1991, 
Hosoda et al., 1996). Sublancin, produced from B. subtilis 168, is a 37 amino acid 
peptide which contains one meLan and two disulphide bridges. The presence of the 
stabilizing lanthionine bridges along with relatively weak disulphide bridges 
suggests a conformational uniqueness which could confer a selective advantage 
(Paik et al., 1998). Lactocin S, produced from of L. sake L45, is a 37 amino acid 
lantibiotic (Mortvedt et al., 1991, Skaugen et al., 1997). This lantibiotic is 
noteworthy as a consequence of containing D-alanine residues (Skaugen et al., 
1994). Among lantibiotics only lacticin 3147 shares this trait. At a neutral pH, this 
lantibiotic exhibits a net neutral charge (Rawlinson et al., 2002). Finally, cytolysin is 
a two peptide lantibiotic (CylLL and CylLS) produced by enterococci which is unique 
by virtue of its ability to target both eukaryotic and prokaryotic cells (Booth et al., 
1996). 
 
1.6 Current and Future Use of Lantibiotics for Food 
Applications 
 
The most prominent event in the majority of food fermentations is the 
conversion of sugars to lactic acid by the LAB. In addition to lactic acid, LAB can 
produce other metabolites with antimicrobial activity such as hydrogen peroxide, 
diacetyl, acetoin and bacteriocins, including a number of lantibiotics such as nisin A. 
Highlights in the industrial application of nisin A as a food preservative include its 
initial use by the food industry in 1953 and its approval by the World Health 
Organization, European Union and US FDA in 1969, 1983 and 1988, respectively. 
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Currently, nisin A has been approved for use in over 48 countries worldwide 
(Delves-Broughton et al., 1996, Cotter et al., 2005, Deegan et al., 2006). There are a 
number of ways via which nisin can be added to a food. This includes the direct 
application of the peptide, in a highly purified form if necessary, as an ‘additive’ 
(being one of only two authorised, natural food antimicrobials; the other being the 
anti-mould additive natamycin), the introduction of a nisin-producing bacteria, as a 
starter or an adjunct culture, to a fermented food (and the subsequent production of 
nisin in situ) or the producer can be used to make a food-grade fermentate, which can 
be dried to make a powdered ‘ingredient’. This powder can then be incorporated into 
either fermented or non-fermented foods. In the case of nisin, all three alternatives 
are employed e.g. ‘Additive’ Nisaplin (from Danisco; 
http://www.daniscocare4u.com/nisaplin.html), Nisin-producing cultures (from 
culture providers such as Christian Hansen and CSK) or ‘Ingredient’ DURAfresh® 
(from Kerry).  
Other than nisin, lacticin 3147 and lacticin 481 are the two most extensively 
studied LAB lantibiotics. Both exhibit traits that suggest they have commercial value 
and a few selected examples of potential applications are presented here. In the case 
of lacticin 3147 it has been established that lactococcal producers thereof can be 
employed as starter cultures for the manufacture of cheddar cheese (Ryan et al., 
1996). Here lacticin 3147 producers successfully reduce the pH of the milk to 5.2 
while also generating sufficient quantities of the lantibiotic to control the 
adventitious non-starter lactic acid bacteria (NSLAB) over a six-month ripening 
period (Ryan et al., 1996). This is significant as NSLAB can be the cause of flavour 
defects and calcium lactate formation (Thomas & Crow, 1983) . The use of lacticin 
481-producing strains as adjunct cultures in cheese production has also been mooted 
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(O'Sullivan et al., 2003). This lantibiotic, which is produced by Lactococcus lactis 
strains (Piard et al., 1992), demonstrates a higher ability to lyse sensitive lactococci 
than lacticin 3147 when used in combination with the starter culture L. lactis HP. 
The associated benefits are the release of intracellular enzymes, thereby speeding up 
the ripening process, and a reduction in the numbers of NSLAB (O'Sullivan et al., 
2003). Studies investigating the use of a lacticin 3147-based powder as a bio-
preservative have also yielded interesting results (Morgan et al., 2001). Like nisin, a 
fermentate containing lacticin 3147 provides an alternative means of introducing the 
lantibiotic into food. Incorporation of a whey powder (10%), which was fermented 
with a lacticin 3147 producer, has been found to bring about a 99.9% reduction in 
Listeria monocytogenes in natural yoghurt and an 85% reduction in pathogen 
numbers in a cottage cheese sample within a two hour time frame. It has also been 
established that an 80% reduction in Bacillus cereus numbers occurs within three 
hours when this powder is added (1% powder) to soup. For a comprehensive review 
on the use of bacteriocins as biological agents for food safety see Deegan et al. 
(2006). 
 
1.7 Lantibiotics and their medical applications 
 
The possibility of using lantibiotics to control or treat multi-drug resistant 
forms of pathogens such as Staphylococcus aureus, Enterococcus species and 
Clostridium difficile has gained increased attention in recent years due to a number 
of positive results obtained by researchers in the field (for a comprehensive review 
please refer to Piper et al. (2009a). In vitro, many lantibiotics, including lacticin 
3147, mutacin B-Ny266, nisin, mutacin 1140, show activity against clinical targets 
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such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus faecalis (VRE), Propionibacterium acne, Streptococcus mutans, 
Streptococcus pyogenes, Streptococcus pneumoniae, Clostridium difficile, Listeria 
and Bacillus species  (Severina et al., 1998, Galvin et al., 1999, Mota-Meira et al., 
2000, Brumfitt et al., 2002, Rea et al., 2007, Ghobrial et al., 2009, Piper et al., 
2009b). It is also interesting to note that both Pep 5 and epidermin successfully 
inhibit the adhesion of staphylococcal cells to the surfaces of catheters (Fontana et 
al., 2006). It is important to note, however, that these represent just a selection of the 
studies which have highlighted the efficacy of lantibiotics against Gram-positive 
clinical pathogens. It is anticipated that the number of studies in this area will 
continue to increase as a consequence of the further investigation of existing 
lantibiotic peptides and the continued identification of new forms of these 
antimicrobials. Some recent examples of note include the two peptide lantibiotic, 
lichenicidin, which exhibits antimicrobial activity against MRSA and VRE strains 
(Begley et al., 2009) and microbisporicin, active against MRSA, VRE and clinical 
streptococci (Castiglione et al., 2008).  
While the in vitro success of a chemotherapeutic agent does not always 
correspond to its in vivo efficacy, there have been a number of studies which indicate 
that this may not be a major failing of lantibiotics. It has been revealed that mutacin 
B-Ny266 can be as active as vancomycin against MRSA in vivo (Mota-Meira et al., 
2005), mersacidin can be employed to eradicate a nasal MRSA infection 
(Kruszewska et al., 2004) and that nisin F, both alone and when used in combination 
with lysozyme and lactoferrin, can successfully treat respiratory tract MRSA 
infections in mice (De Kwaadsteniet et al., 2009). Trials investigating the use of 
lantibiotics to control the microorganisms responsible for dental plaque, halitosis, 
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‘strep’ throat (Hillman, 2002, Burton et al., 2006, Dierksen et al., 2007) and even 
bovine mastitis (Ryan et al., 1999, Twomey et al., 2000) have also all been 
successful.  
1.8 Engineering of lantibiotics 
 
Lantibiotics are gene encoded and thus one can take advantage of this trait in 
order to engineer novel variants of the parent peptide. Such variants have been used 
to study structure/ function relationships and, in some cases, engineering strategies 
have led to the generation of peptides with enhanced antimicrobial activity. 
Lantibiotic engineering can take place in vivo, i.e. by manipulating the original 
producing strain or expressing the genes heterologously in an alternative host, or in 
vitro, i.e. harnessing the activity of purified forms of the individual components of 
biosynthetic machinery outside of a host. The application of engineering in 
lantibiotic research commenced in 1992. Although initial nisin-focused 
investigations did not lead to the production of variants with enhanced activity 
(Kuipers et al., 1992), they clearly demonstrated the power of this technology. 
During the same year the extreme consequences of making single deliberate amino 
acid changes was demonstrated when it was established that a single residue change 
in subtilin resulted in a 57-fold increase in its biological and chemical stability (Liu 
& Hansen, 1992). This technology has continued to be applied and in 2006 the first 
alanine-scanning mutagenesis of a lantibiotic, lacticin 3147, was completed (Cotter 
et al., 2006). In this study, alanine (or glycine in cases where an alanine was already 
present) was introduced in place of the 59 amino acids, in turn, and the impact on the 
antimicrobial activity of the associated producing strain was quantified. The data 
generated highlighted specific areas of the peptides in which subsequent site specific 
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mutagenesis approaches might be beneficial. This strategy was taken a step further 
when site-saturation mutagenesis was employed to engineer both nukacin ISK-1 
(Islam et al., 2009) and mersacidin (Appleyard et al., 2009). Both studies provided 
an in-depth insight into the structure-function relationships within the respective 
peptides and, in the case of nukacin ISK-1, two variants which displayed a two-fold 
increase in specific activity were identified (Islam et al., 2009). The use of 
engineering to study/improve nisin has also continued at pace and since the 1990s 
this lantibiotic has been the subject of a number of engineering-based strategies 
which have employed site-directed, site-saturation and/ or random mutagenesis. 
While various different regions of the peptide have been engineered, the N-terminal 
and ‘hinge’ regions have been the focus of greatest attention. The benefits of 
manipulating the hinge (consisting of Asn20-Met21-Lys22) have been particularly 
notable (Yuan et al., 2004, Field et al., 2008). Yuan and co-workers employed a site-
directed approach whereby either positively or negatively charged amino acids were 
introduced into the hinge. These studies demonstrated that specific changes (i.e. 
N20K and M21K) increased the activity of the peptide against Gram-negative 
bacteria such as Shigella species., Pseudomonas species. and Salmonella species. In 
the case of Field et al., screening of a bank of random mutagenised nisin variants 
revealed that a K22T variant displayed enhanced activity against the mastitic 
pathogen Streptococcus agalactiae. This prompted the use of site-saturation 
mutagenesis (Field et al., 2008) for each of the individual hinge residues which, 
when coupled with a larger selection of target strains, lead to the identification of a 
number of peptides with enhanced activity against Streptococcus agalactiae, 
Staphylococcus aureus and Listeria monocytogenes. Yet another study, focusing on 
rings A and B at the N-terminal end of nisin A, showed that the various activities of 
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nisin can be altered by changing the amino acid arrangement in this region of the 
peptide (Rink et al., 2007). Two mutants, designated KFI and KSI (letters indicate 
the amino acids present at positions 4, 5 and 6), displayed increased antimicrobial 
activity against a number of bacteria such as Leuconostoc mesenteroides, 
Lactobacillus johnsonii and Lactoccus lactis. KFI, and another variant VFG, also 
inhibited the outgrowth of Bacillus subtilis 168 spores more effectively than the 
wild-type.  
It should be noted that these and other (bio)engineering-related strategies 
have also been used for a variety of other purposes such as increasing lantibiotic 
production (Cotter et al., 2006, Heinzmann et al., 2006), introducing lanthionines 
into class II bacteriocins (Majchrzykiewicz et al., 2010) and even the post-
translational modification of other bioactive peptides (Kuipers et al., 2004, Kluskens 
et al., 2009, Rink et al., In Press). In addition to these approaches, the ever-
improving ability of chemists to generate lantibiotic-like peptides through synthetic 
chemistry (Cobb & Vederas, 2007, Arnusch et al., 2008, Ross et al., 2010) is 
particularly exciting and has already facilitated the creation of potent nisin-
vancomycin hybrids (Arnusch et al., 2008). 
 
1.9 Screening for new lantibiotics 
 
While scientists are continuing with their efforts to further improve known 
lantibiotics, there is still considerable merit attached to identifying new peptides. It 
has also become apparent in recent years that the use of bioinformatics can be a very 
useful means of screening for such novel lantibiotics. The availability of databases, 
including both general (NCBI) and dedicated (BAGEL and BACTIBASE (de Jong et 
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al., 2006, Hammami et al., 2007, Hammami et al., 2010)), has facilitated the use of 
in silico approaches to lantibiotic screening. The two-peptide lantibiotic lichenicidin 
(Begley et al., 2009) was identified using such an approach. Here, the highly 
conserved nature of the lanM gene was exploited to screen the ever increasing 
number of bacterial genome sequences that are publicly available. Initial screening 
revealed 89 lanM genes of which 61 had not previously been associated with 
lantibiotic production. One of the potential novel lantibiotic producers identified, B. 
licheniformis ATCC 14580, was selected and from it lichenicidin was isolated 
(Begley et al., 2009). A similar approach was previously employed to identify 
another two-peptide lantibiotic, haloduracin, which is produced by Bacillus 
halodurans C-125 (McClerren et al., 2006, Lawton et al., 2007). Bioinformatics has 
also been of considerable use when designing engineered lantibiotics and novel 
lanthionine-containing peptides. A study by Rink and co-workers (Rink et al., 2005) 
used bioinformatics to predict the impact of flanking amino acids on the dehydration 
of serine and threonine residues, and subsequent (me)Lan formation, in lantibiotic 
peptides. An in silico comparison of known lantibiotics found that the majority of 
modified serines and threonines were flanked by hydrophobic residues. In silico 
models predicted the likely impact of specific residues on modification when located 
adjacent to hydroxyl-amino acid residues. The subsequent creation, and 
investigation, of these peptides validated this theory. 
 The discovery of the lantibiotics microbisporisin and planosporicin was 
achieved using a more traditional screening method (Castiglione et al., 2007, 
Castiglione et al., 2008) involving120,000 broth extracts obtained by fermenting 
40,000 actinomycetes. Firstly the microbial products were screened to assess their 
activity against S. aureus before then selecting those which retained activity 
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following exposure to a β-lactamase cocktail or D-alanyl-D-alanine affinity resin i.e. 
were neither β-lactams nor vancomycin-like glycopeptides. Those which retained 
antimicrobial activity after these steps were selected for further investigation. This 
strategy yielded thirty-five lantibiotics, of which five showed little or no similarity to 
any known lantibiotics. 
1.10 Outlook 
 
The lantibiotic class of bacteriocins has the potential to be employed in a 
wide variety of different ways. As outlined above they have shown great promise as 
chemotherapeutics that can target the multi-drug resistant Gram-positive clinical 
pathogens, including the particularly problematic pathogens MRSA, VRE and 
Clostridium difficile. A number of these peptides are particularly attractive as a 
consequence of research that has established that they have mechanisms of action 
and target binding sites that are distinct from those of non-lantibiotics. This coupled 
with high potency and their generally non-cytotoxic nature could lead to these 
compounds having clinical applications in the future. The possibility of engineering 
new and improved lantibiotics, producing novel chemotherapeutics through the 
fusion of lantibiotics with antibiotics, the introduction of the lantibiotic-associated 
modifications into non-lantibiotics and the chemical synthesis of new lantibiotic-like 
peptides, as well as the ongoing use of traditional and in silico strategies to find 
novel compounds, all bring this potential to a new level. In addition to these new 
markets, it should not be forgotten that a lantibiotic, nisin, has been successfully 
employed by the food industry for over a half century. Other lantibiotics have the 
potential to be similarly employed and, as a consequence of the limited activity of 
nisin against certain target strains and species, together with its poor activity at 
25 
 
neutral pH, there are obvious niche-markets that these can fill. The commercial 
potential of lantibiotics and lantibiotic-related technology and the cutting edge 
fundamental science that underpins lantibiotic research will ensure that these 
peptides will continue to attract great attention in the coming years. 
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1.13 Figures  
Figure 1.1 Lantibiotic classification 
 
Lantibiotics can be divided into Type I, II and III peptides. The Type I and II peptides can be further 
divided into 12 groups on the basis of the sequence of the lantibiotic propeptide. In one representative 
case, the mersacidin-like peptides, each of the corresponding propeptides are listed and aligned. 
Amino acids that are 100% conserved are highlighted in black. 
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Figure 1.2 Representative lantibiotic structures 
 
Modified residues are coloured (dehydrobutyrine – Dhb, green; dehydroalanine – Dha, orange; 
lanthionineAla-S-Ala, yellow; β-methyllanthionine – Abu-S-Ala, light blue; D-alanine – Ala, grey; 
lysinoalanine – Lys-NH-Ala; other modified residues - pink). 
 
 
 
 
 
 
 
S
10
15
Ile Dhb Ala
Ile
Dha
Leu
Ala Abu
Pro Gly
Ala Asn
Ala
Abu
Ala
His
Gly
Abu
Ala
Leu
Gly
Ala
Met
S
Met Lys Abu Ala Dha LysSer Ile His ValLys
S
S
S Nisin A5
20
25
30
Dhb Ala IlePro Ala Dhb Pro Ala Ile Leu Ala Ala Tyr Ile
Ltn
Ala Ala
Asn
S
Thr Thr
Pro Abu Ala
S
Arg Ala
Abu Ala
S
Thr Lys5 10 15 20 25
Abu Leu Ala
Ala
His
S
Asp
Tyr
Asn
Trp
Gly
Asp
AlaAla
Gly
PheAla Dhb Asn Ala LeuAla Dhb
Ala
Trp
Abu
Glu
Ala
Trp
Met
Lys
S
S
Ltn
S
5
10
15
20
25
30
Abu
Ile
Ala
His
Glu
Ala
Asn
Met
Asn
Ala
Trp
Gln
S
S
Val IleLys Gly Gly Ser HisGly
Ala
Phe
Val
PheDhb
Ala
Ser
S
Lacticin 481
Lys Abu
Asn
Gly Asp
Ala
Abu
Phe
Pro
Gly
Phe
AlaAla
Ala
GlnAla
S
S
S
Arg
Val Phe
H
N
5
15
Cinnamycin
Ala
Ile
S
Ala
S
Ser
Gly Trp
Val
Ala
Abu
Leu
Abu Ile
Glu
Ala
S
S
Gly
Abu
Val
Ala Ala
O
Actagardine
12
8
17
4
Val Dhb Ala
cTrp
Dha
Leu
Ala
Abu
GlyPro
Ala
Thr
Ala
rPro
Phe
Gly
Gly
Ala
Asn
Ala Ala
Ala
Gly
4
8
16
12
19
21
S
S
S
S
S
NH
Microbisporicin
S
Ile Dhb Ala
Val
Dha
Trp
Ala
Abu
Ala
Thr
Ala
S
Glu
Gly Gly
Gly
Gly
Gly
Ala
Ala
S
Ala
His
S
Pro
Planosporicin
Ala
Ala
S
5
10
15
20
Ala Dha
Ile
Ile
Lys
Dhb
Dhb Ile
Lys
Val
Ala Lys
Ala
Val
Ala
S
Lys
Abu
Leu
Abu
Ala
S Ile
Ala
S
Abu
Ala
S
Gly
Ala
Dha
Asn
Ala
S
Lys
O
H
3
C
Paenibacillin
5
10
15 20
25
30Leu
Asn
Lys
AsnTyr
Trp
Ala
Gly
Ala
Tyr
Ile
Ala
S
Ala
Ser
Arg
Leu
Gly
Abu Abu
Pro
Met
Glu
Val
Ala
Ala
S
Asn
S
NH
SSO
H 2 N
O
Abu
Ala
Dhb
Dhb
Ala
Val
Pro
Trp
Ala
S
Val
Gly
Val
Ala
Ser
Lys
Pro
Leu
S
Abu
Abu Dhb
Ala
Ala
S
Gln
S
Haloduracin
ArgAlaIleAla Dhb
Lys
LysVal DhbDhb Ile Lys Ala
Leu
Lys
Ala
S
Gly Phe Ala
Lys
Ala
Ala
Gly
Ala
S
PheHis Dhb Gly Lys Lys
S
Epilancin 15X
C
O
CH
OH
CH
3
C
CH2
CO
O
CH3
Mersacidin
NH
CH
CH
Ala Abu Phe
Pro
Abu
Leu
Gly
Gly
Abu
Leu
Abu Dha
Glu
Ala Ile
Gly
Ala
Val
Gly
S
S
S
S
17
5
10
15
r
r r
Haloduracin 

39 
 
Chapter II 
 
Fate of Mycobacterium avium subspecies 
paratuberculosis ATCC19698 during Manufacture 
and Ripening of a Non-Pasteurised Smear Type 
Cheese made with and without Lacticin 3147. 
 
Brian Healy, Mary C. Rea, R. Paul Ross, Colin Hill and Paul D. Cotter 
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2.1 Abstract 
 
Mycobacterium avium subspecies paratuberculosis (MAP) is an obligate 
pathogenic bacterium which is the causative agent for Johne’s disease, a localized 
chronic infection of the lower intestine (ileum) of animals. MAP has also been 
implicated in Crohn’s disease in humans, although this association remains highly 
controversial. There has also been considerable debate as to whether or not the 
microorganism can withstand HTST (High Temperature Short Time) pasteurization. 
Therefore, until it can be definitively established that the consumption of MAP 
infected food does not lead to human infections, the elimination of this pathogen 
from the food chain would be prudent.  
In this study, an additional hurdle was introduced into a dairy product in 
order to determine if it provided additional protection against MAP. More 
specifically, a lacticin 3147 producing starter culture was employed for the 
production of smear ripened raw milk cheese.  Lacticin 3147 is a two peptide 
bacteriocin (Bac) produced by a number of Lactococcus lactis strains, has been 
comprehensively characterised and has been shown to inhibit many clinically 
relevant Gram-positive pathogens, including MAP. Two separate cheeses were 
produced using either Bac
+
 or Bac
- 
versions of the same starter culture. Both were 
allowed to ripen for 4 weeks after the addition of the smear and along with the ‘gold 
standard’ plate enumeration method, the viability of the pathogen was also 
determined using a molecular approach.  
Although some decrease in MAP numbers was observed over ripening, this 
decrease was independent of lacticin 3147 production. Thus, other strategies will 
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need to be tested with a view to harnessing the anti-MAP activity of this bacteriocin 
in dairy products. 
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2.2 Introduction 
 
Mycobacterium avium subspecies paratuberculosis (MAP) is an obligate 
pathogenic bacterium and is the causative agent of Johne’s disease (Cocito et al., 
1994), a localized infection of the lower intestine (ileum) which mainly affects  
ruminants. The resulting lesions from this chronic enteritis are similar to those 
present in the intestines of patients with Crohn’s disease (Davis & Madsen-Bouterse, 
2012), consistent with suggestions that this bacterium also contributes to this disease. 
However, a definite link between MAP and Crohn’s disease has yet to be established 
and conflicting research outcomes (Hermon-Taylor, 2002, Momotani et al., 2012) on 
this subject continues to evoke much debate.   
In Ireland it is apparent that the levels of Johne’s disease are on the rise. The 
opening up of the Single European market in 1992 is thought to have contributed to 
this increase. In 1955, Johne’s disease became notifiable (S.I. No. 86 of 1955) 
although only 92 cases were reported between 1932 and 1992, despite the payment 
of compensation for confirmed cases. In stark contrast, 232 cases were reported 
between 1995 and 2002 (Good et al., 2009). As well as the associated economic 
implications (culling, lower milk and beef yields, veterinary costs), the potential for 
significant increases in the frequency of MAP-containing milk is of concern. Indeed, 
infected animals excrete the bacterium in large numbers, which contributes greatly to 
the subsequent infection of calves and the contamination of milk (Fecteau & 
Whitlock, 2010). This, coupled with MAP’s ability to survive outside its host for 
extended periods of time (Rowe & Grant, 2006) and the possibility of the bacterium 
surviving pasteurisation, another disputed issue (Lynch et al., 1997, Grant et al., 
2002), highlights a route via which the pathogen could enter the human food chain. 
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It is thus a concern that the pathogen has been identified in off-the-shelf dairy 
products. Out of 357 commercially pasteurized milk samples from Ireland tested, 
9.8% were found to be PCR positive for MAP (O'Reilly et al., 2004) while, in the 
US, 2.8% of 702  pasteurised milk samples were found to be culture positive 
(Ellingson et al., 2005). In the latter case, given the fastidious nature of the strain, 
this is likely to be a significant under-representation. Given that Irish exports of milk 
and milk products make a very significant contribution to Irish national GDP, the 
elimination of any potential zoonotic pathogens from the Irish milk can only be seen 
as prudent both from a public health and economic perspective. 
One potential method to increase the safety of dairy products is through the 
introduction of additional barriers to aid in the eradication of pathogenic bacteria. 
One such barrier is the use of bacteriocins (Deegan et al., 2006, Gálvez et al., 2007). 
Defined as ribosomally synthesised antimicrobial peptides (Cotter et al., 2005), 
many bacteriocins are produced by lactic acid bacteria. One such strain is 
Lactococcus lactis DPC 3147, which produces the Class 1 bacteriocin, lacticin 3147 
(Ryan et al., 1996). L. lactis are also the most important industrial starter cultures, 
both from a biotechnological and economic viewpoint (Bolotin et al., 2001, Fox et 
al., 2004). The selection of technologically superior strains is based on a number of 
traits such as rapid lactose metabolism, proteolytic activity, citrate metabolism, 
bacteriophage resistance, antibiotic resistance, exopolysaccharide (EPS) production 
and bacteriocin production (Dal Bello et al., 2012). Importantly, many of these traits 
are plasmid encoded and their self-transmissible nature has been exploited to 
improve the genotypes of industrial starters in a food grade manner (Mills et al., 
2006).  
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L. lactis DPC 3147 harbours the 60.2 kb plasmid pMRC01. This plasmid 
carries genes involved in conjugative transfer, phage resistance through abortive 
infection and the production of and immunity to the lantibiotic, lacticin 3147 
(Coakley et al., 1997). Lantibiotics are distinguished by the presence of rare amino 
acids found within their mature structures, resulting from a number of post-
translational modifications (Healy et al., 2010). Two of these, dehydroalanine and 
dehydrobutyrine, are involved in the formation of the lanthionine bridges, the 
structures that give these antimicrobials their name. The mode of action of lacticin 
3147 is two-fold and involves the synergistic interaction of its two component 
peptides, Ltnα and Ltnβ, leading to the sequestration of essential peptidoglycan 
precursors and pore formation (McAuliffe et al., 1998, Wiedemann et al., 2006). 
Like many lantibiotics, lacticin 3147 displays activity in the micro to nano-molar 
range against many clinically significant pathogens (Piper et al., 2009a, Piper et al., 
2009b, Iancu et al., 2012).  
There are numerous ways in which lantibiotics can be used in order to 
enhance the safety of a food(see Deegan et al. (2006) for an extensive review on this 
topic). In this study, an in situ method of production by a starter culture in the 
manufacture of a smear ripened cheese from unpasteurized milk was assessed as a 
means of controlling the growth of MAP. Smear ripened cheeses are characterised by 
the development of microbial growth on their surfaces during ripening (Brennan et 
al., 2004). A previous study, by O'Sullivan et al. (2006), showed that the 
introduction of a lacticin 3147 producing L. lactis culture to the surface of a smear-
ripened cheese led to a 100-fold decrease in Listeria monocytogenes numbers. Here, 
two smear ripened cheeses were manufactured to assess the survival of MAP over a 
28 day ripening period. The first cheese was made with a lacticin 3147 producing 
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starter culture while the second was made with a non-bacteriocin producing 
equivalent and served as a control. It was found that although an approximate 1 log 
reduction in MAP numbers occurred over the ripening period, this reduction occurred 
regardless of which starter strain was used and, thus, was independent of bacteriocin 
production.  
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2.3 Materials and Methods  
 
2.3.1 Bacterial strains and growth conditions 
 
The strains used in this study are listed in Table 2.1. All L. lactis strains were grown 
on/ in M17 agar and broth (Oxoid) supplemented with 0.5% lactose and incubated at 
30
o
C overnight. MAP ATCC19698 was grown on Middlebrook 7H9 broth (Becton 
Dickenson) containing 10% oleic acid-albumin-dextrose-catalase (OADC) 
supplement (Becton Dickinson) and 0.05% Tween 80. Mycobactine J was added at 2 
µg/ ml (Synbiotics Europe) while vancomycin, nalidixic acid and amphotericin B 
were added at concentrations of 17.5 µg /ml, 17.5 µg/ ml and 12.5 µg/ ml, 
respectively. Incubation was for 37°C for up to 6 weeks with constant gentle 
agitation. For enumeration, MAP was also grown on Middlebrook 7H10 agar 
(Becton Dickinson) and Herrold’s Egg Yolk agar (HEYA) (Becton Dickenson), with 
the same supplements and antibiotics as for 7H9 agar. Due to the long incubation 
times required, all enumerations were carried out in 25 cm
3 
culture flasks so as to 
prevent dehydration of the agar (Sarstedt). 
2.3.2 Production of smeared cheese from unpasteurised milk 
 
Twenty litres of unpasteurized milk were collected from bulk milk tanks on the 
Moorepark Farm and refrigerated at 4ºC. Samples were analysed to determine total 
bacterial counts (TBCs) on Milk Plate Count Agar (MPCA), somatic cell counts 
(SCCs), %fat, %lactose, %protein (all using a MilkoScan 600) and to test for the 
absence of antibiotics (Delvo test). 10 l of milk were added to two separate vats and 
heated. At 20ºC, 1.5% (v/v) of L. lactis DPC3147 (lacticin 3147 producing starter 
culture) and 1.5% (v/v) of L. lactis DPC5399 (non lacticin 3147 producing starter 
culture) were inoculated into separate vats. At 30ºC, 15 ml of the MAP strain (~1.0 x 
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10
9
 cfu/ml) was added to each vat to give a final concentration of ~10
5 
cfu/ml and 
mixed well. Once a pH of 6.55 was reached, 1.6 ml/l of rennet was added to each vat 
and the milk was left to coagulate for 75 minutes. The curd was cut and allowed to 
rest for 5 minutes. With constant stirring, both samples were cooked to 36ºC over 30 
min increasing the temperature by 1ºC every 5 min. After cooking, the curd was 
stirred gently until a pH of 6.0 was reached. At this stage the curd from each vat was 
added tightly to 6 moulds. These moulds were turned every 30min for the first 3hrs 
and twice more bringing the total time post-moulding to 5hrs when the moulds were 
kept at 8ºC overnight. The moulds were next brined in 23% sterile NaCl containing 
200 µg/l Ca
2+
 for 75 min followed by drainage for 10 min. The cheese was then 
smeared with Lyrofast SRC1 (Sacco; 1.25 g/250 ml sterile water) and incubated at 
13-15°C with 95% relative humidity. The cheeses were turned daily and washed in 
brine solution every two days. The smear was applied again after day 5. After 2 
weeks, the cheeses were moved to an 8°C incubator and allowed to ripen for a 
further 2 weeks. 
2.3.3 Sampling routine 
 
2.3.3.1 MAP enumeration 
The raw milk from the bulk tanks was tested to ensure the absence of MAP. The 
cheese was sampled immediately post smearing (T0) and weekly for 4 weeks during 
ripening. At each sampling time 5 g of a representative sample (wedge) was 
homogenised in 2% tri sodium citrate. 100 µl of dilution was added to HEYA and 
7H10 agar in 25cm
3
 culture flask with the relevant selection agents and supplements 
added. Cetylpyridinium chloride (CPC) (Sigma Chemicals, MO, USA) was added at 
a concentration of 0.001% to a duplicate of each sample to decrease background 
contamination. These flasks were incubated at 37°C for 8 weeks. 
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2.3.3.2 Salt, moisture and pH 
 
All three parameters were determined for both the surface and interior of the cheese 
using standard methods as described by Lynch et al. (1997). Salt concentrations were 
determined after two weeks of ripening (T2). Measurements were taken to determine 
moisture and pH immediately post smearing and weekly during ripening.  
2.3.4 Detection of lacticin 3147  
 
Well diffusion assays were carried out in LM17 agar seeded (0.5% v/v) with either 
L. lactis HP (lacticin 3147 sensitive) or L. lactis HP pMRC01 (lacticin 3147 
resistant). 2 g of cheese at T0 (addition of smear) and at week 1, 2, 3 and 4 of 
ripening was added to 2 ml of 2% tri-sodium citrate, homogenised and centrifuged 
for 5 min at 13000 rpm. The fat layer was removed with sterile pipette and 50 µl of 
the supernatant was added to wells in the seeded plates followed by incubation 
overnight at 30ºC. The production of lacticin 3147 was evident through the 
production of zones against the HP indicator that were not apparent when the HP 
pMRC01 indicator was used. 
2.3.5 Confirmation of MAP colonies through PCR 
 
Two separate primer sets (L1 and L2, and AV1 and AV2) (Table 2.2), which target 
the same MAP-specific gene (IS900), were employed to confirm the identification of 
colonies on 7H10 plates. Template DNA was acquired from colonies through 
IGEPAL denaturation (5 µl incubated 94ºC for 10 min). PCR mix (other than 
primers used, 50 µl total volume) and cycling conditions were the same for both 
reactions. The PCR mix consisted of 5 µl 10X Buffer for KOD Hot Start DNA 
Polymerase, 3 µl 25mM MgSO4, 5 µl of 2 mM dNTPs, 2.5 µl 0.2 µM forward and 
reverse primer, 5 µl of template from previous reaction, 1 µl of KOD Hot Start DNA 
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Polymerase (1U µl) (Novagen) and 26 µl of H2O. Initial denaturation at 95ºC for 2 
min followed by 30 cycles of 95ºC for 20 sec, 58ºC for 10 sec and 72ºC for 15 sec 
with a final extension of 72ºC for 5 min. 
2.3.6 Molecular Quantification using RT-PCR  
 
2.3.6.1 Sample preparation prior to DNA extraction 
 
Duplicate 5g samples of cheese from each sample period were diluted 1:10 in cheese 
diluent composed of 0.5% (wt/vol) sodium chloride, 1% (wt/vol) Casitone (Difco), 
and 2% (wt/vol) sodium citrate. This mixture was next stomached at 260 rpm for 4 
min. The samples were incubated for hr at 37ºC shaking at 90ºC followed by 
stomaching at the same conditions as above. This mix was then centrifuged for 15 
min at 4000 rpm. The supernatant was removed and the remaining pelleted 
resuspended in 10 ml of phosphate buffered saline. 
2.3.6.2 DNA Extraction 
 
DNA extraction was achieved using an Adiapure paraTB Milk kit (Adiagene). The 
procedure was carried out as stated in manufacturer’s instructions. In brief, MAP 
DNA was separated through the specific capture of MAP cells on magnetic beads 
with subsequent grinding to destroy the cell wall. 
2.3.6.3 Real-Time-PCR  
 
This method used was based on that developed by Rodriguez-Lazaro et al. (2005). 
The target area for the RT-PCR was the IS900 insertion sequence in the MAP 
genome. Applied Biosystems® 7500 Fast Real-Time PCR System was used for the 
analysis. Taqman® Universal PCR MasterMix (Applied Biosystems®) was used as 
per manufacturer’s specifications. To ensure fluorescence was not being inhibited, a 
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Taqman IPC (Applied Cat. No.43083223) was included. The primers and probe used 
are listed on Table 2.2. 
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2.4 Results 
 
For this study, two separate cheese trials were carried with the aim of 
determining if MAP could survive the process involved in the production of a smear 
ripened cheese from raw milk. The second goal was to determine if the presence of a 
lacticin 3147-producing starter culture could provide an additional means of 
eradicating this pathogen from the human food chain. Finally, a comparison was 
made between the ‘gold standard’ plate based enumeration method with a molecular 
quantification technique to quantify MAP levels. 
As the cheese was made from raw unpasteurised milk, a high microbial load 
was to be expected both after manufacture and during ripening. Added to this was 
the large consortium of bacteria arising from the smear that was applied post 
production. These features and the extremely fastidious nature of the pathogen meant 
that isolation of MAP at low levels was impractical. Thus, it was decided that the 
starting inoculum for the MAP strain in the raw milk was to be approximately 10
5 
cfu/ml. 
The raw milk for this trial was obtained from the bulk milk tank from the 
Teagasc Moorepark farm. Table 2.3 displays the percentage fat, the percentage 
lactose and the percentage protein - all of which were at acceptable limits. The total 
bacterial count and the somatic cell count were also below stated limits (Regulation 
(EC) No. 853/2004) and no antibiotic residues were detected. The smear ripened 
cheese make procedure was carried out as outlined in the materials and methods 
section. Along with the enumeration of MAP during the ripening procedure, the 
percentage moisture and pH was recorded at Day 0 (addition of the smear), and 
weekly for a period of four weeks.  
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Figure 2.1, panels A-E shows the development of the smear over the ripening 
period. For this study a fast-growing commercial blend was used, Lyrofast SRC1 
(Sacco), a blend which consists of specifically selected strains of Debaryomyces 
hansenii, Staphylococcus xylosus, Arthrobacter globiformis, Brevibacterium linens 
and Geotrichum candidum. The low starting pH favours the growth of D. hansenii 
and G. candidum which in turn increases the pH leading to conditions that favour the 
growth of the remaining members of the consortium. During this process the smear 
develops on the surface resulting in a softening of the cheese through the proteolytic 
and lipolytic action of the smear bacteria. As the smear develops a yellow colour 
appears on the surface.  
The percentage moisture, for both the surface and the interior of the cheese, 
was monitored (Figure 2.2). Unlike cheeses such as cheddar or Gouda, which are 
either vacuum-packed in plastic or have a wax coat applied during ripening, a smear 
type cheese is ripened without any physical protection. In order to protect the cheese 
from moisture loss, ripening took place within a humidity controlled chamber. While 
some variation was noted for the % moisture on the surface of both cheeses at day 
28, moisture levels which ranged from 44% up to 60% were within the accepted 
guidelines for a smear type cheese.  
As is normal for a smear type cheese, the pH (Figure 2.3) on the surface 
increased from pH 5.1 on Day 0 to over pH 7.0 at the end of ripening for both the 
control and lacticin 3147 containing cheese. This increase corresponds to the 
development of the smear. A more subtle rise in pH was seen for the interior of both 
cheeses with a difference of 0.2 pH units observed. Both the percentage moisture and 
pH results shown here are averages of both trials.  
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Unlike Cheddar, which is dry salted before pressing, smear cheeses are brine 
salted after molding. As time is needed for the migration of the salt from exterior to 
interior, and to eventually reach an equilibrium, the percentage salt was measured 
after 2 weeks ripening. Samples were taken from the surface, the interior and 
midway. The mean of these three values was averaged from both trials and the 
standard deviation determined. The percentage salt for the control cheese was 1.4 
with a SD of 0.106 while the lacticin 3147 containing cheese was 1.5 with a SD of 
0.213. Both figures fall within acceptable norms for this type of cheese.  
Well diffusion assays were employed to ensure that lacticin 3147 was 
produced at all stages during ripening. L. lactis HP was used as a lacticin 3147 
sensitive indicator while a derivative of HP that contains a plasmid, pMRC01, 
encoding for immunity to the lantibiotic was also used to ensure than any inhibition 
was due to the lacticin 3147 specifically and not another inhibitor in the cheese 
matrix. In all cases, no lacticin 3147 production was detected in the control cheese 
while a zone of inhibition was observed in the test cheese throughout ripening (data 
not shown). It was thus apparent that the MAP cells were exposed to lacticin 3147 
from manufacturing to ripening. 
Survival of MAP was monitored over the 28 day ripening period by plating 
on HEYE and 7H10 (Figure 2.4). The initial 1:10 dilution was made in 2% tri-
sodium citrate with subsequent dilutions made in maximum recovery diluent (MRD). 
Each sample was weighed twice. In order to reduce background flora, 0.001% CPC 
was added to one while the second was plated without addition of the antiseptic. At 
T0, MAP cells were detected at ~10
5
 cfu/g in both trials and in both the control and 
lacticin 3147 cheeses. An approximate 1 log reduction was observed for both the 
control and the test cheese over the first two weeks of ripening with this figure 
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remaining constant at the end of week three. By the end of week 4, the levels of 
MAP showed a slight increase. Both the control and the test cheese when treated 
with CPC showed a more constant decrease in cell numbers with a log reduction of 
2.4 observed for each. HEYM was found to be unsuitable for the recovery of MAP 
from raw milk due to the high levels of background contamination present on the 
plates. Therefore all counts were from the 7H10 plates. No difference was observed 
in MAP levels between cheeses containing the lacticin 3147 producing starter culture 
and the control, either with or without the addition of CPC. All presumptive MAP 
colonies were confirmed as MAP through PCR with the use of two IS900 primer 
sets, L1& L2 and AV1 & AV2 (Bull et al., 2003). 
Molecular quantification of the levels of MAP in the cheese samples was 
completed using real-time PCR so as to ascertain whether this was a valid method 
for future studies. The resulting Ct values (Table 2.4) indicate a good replication of 
the trend observed for the plate based enumeration in that a less than 1 log reduction 
was observed over the ripening period and no discernible difference in numbers was 
apparent between cheese containing the lacticin 3147 producing starter culture and 
that produced with the non-bacteriocin producing equivalent.  
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2.5 Discussion 
 
Members of the family Mycobacteriaceae include many slow-growing 
pathogenic species such as Mycobacterium tuberculosis and Mycobacterium leprae, 
the etiological agents of human tuberculosis and leprosy, respectively. Two 
important animal pathogens also belong to this family; Mycobacterium bovis, the 
causative agent of bovine tuberculosis, and Mycobacterium paratuberculosis, the 
causative agent of Johne’s disease. It is the latter bacterium which is the focal point 
of this study. 
Johne’s disease has been detected on every continent (Rowe & Grant, 2006) 
and, due to difficulties in its detection during a sub-clinical period of between 2 to 5 
years (Stabel, 1998), treatment of the condition is challenging. The clinical period of 
infection manifests as a chronic and intermittent diarrhoea leading to contamination 
of the environment and colostrum, with increased herd infection (Cocito et al., 
1994). Infected cattle become increasingly emaciated and die of dehydration and 
severe cachexia. Coupling this with MAP’s innate resistance to chlorine (Whan et 
al., 2001) and processes such as temperature treatments (Grant et al., 2002) afforded 
to it by its waxy cell wall, contaminated milk provides a realistic route for the 
introduction of the bacterium into the human food chain. 
Three questions were addressed in this study. Firstly, does MAP survive 
manufacture and ripening of a smear ripened cheese made from unpasteurized milk? 
Cheeses of this variety are high risk products with respect to contamination by 
pathogens due the risks associated with the use of unpasteurised milk and 
technological factors such as their high moisture content, low salt concentrations and 
short-ripening times. Secondly, does the bacteriocin producing strain L. lactis DPC 
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3147, when used as a starter culture in the same process, impact on the survival of 
the pathogen? Thirdly, we compared the gold standard method of MAP enumeration, 
i.e. culturing on solid media, with a real-time PCR technique targeting the IS900 
insertion sequence (McFadden et al., 1987, Green et al., 1989), which is present at 
14-18 copies per genome. 
Lantibiotics such as nisin and lacticin 3147 have previously demonstrated 
effectiveness against a number of clinically significant mycobacteria (Carroll et al., 
2010). Indeed in that previous study, a purified form of lacticin 3147 displayed 
particularly potent activity against Mycobacterium tuberculosis H37Ra, 
Mycobacterium kansasii CIT11/06 and MAP ATCC19698. This activity provided 
the rational for employing a lacticin 3147 producing starter for this cheese trial. 
Plating on selective agar, without CPC treatment, (Figure 2.4) revealed that 
viable counts of MAP from both the control and lacticin 3147 producing starter-
containing cheeses decreased less than 10-fold after four weeks of ripening. 
Although lacticin 3147 was produced throughout the ripening period, as 
demonstrated by well diffusion assays, it had no effect on MAP numbers. Current 
culture methods do not allow the enumeration of low numbers of MAP in the 
presence of high background microflora found in smear ripened raw milk cheese. In 
this study an artificially high inoculum was used for these reasons. It may be that 
bacteriocin producing cultures would provide significantly improved killing of MAP 
if the levels of the pathogen are within the normal range for naturally contaminated 
milk. As the % moisture, pH and appearance of both the control and the lacticin 
3147 containing cheeses were all within the accepted norms, it could concluded that 
the presence of lacticin 3147 in the cheese matrix, which was present right through 
ripening, did not impact on the bacterial constituent of the smear.  
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When samples were treated with CPC prior to plating, a more dramatic 
decrease in cell numbers was observed. For both the control and the test cheese, a 
greater than 2 log reduction was observed. This decrease is likely due to the inability 
of MAP cells that are sub-lethally injured as a result of the ripening process to 
survive CPC treatment. The similarity in MAP survival levels across the control and 
the test cheeses again highlighted that bacteriocin production did provide enhanced 
protection against the pathogen.  
RT-PCR may be a valuable tool to confirm the viability of MAP in a complex 
matrix, such as smear ripened raw milk cheese, where the bacterial load is extremely 
high and the flora quite diverse. In this study, RT-PCR results confirmed the 
conclusions reached from plate enumeration, including the observation that lacticin 
3147 producing cultures did not offer added protection through inhibition of the 
MAP cultures during cheese ripening in raw milk smear ripened cheese. As noted 
previously, due to sensitivity limits, the starting inoculum was high, which may have 
impacted on the effectiveness of the bacteriocin. As the sensitivity afforded by this 
molecular quantification is lower than that of plate counts, future studies could 
assess the effectiveness of bacteriocins at more realistic levels of MAP 
contamination. 
Although not classed as a zoonotic agent, MAP has often been linked with 
Crohn’s disease, an inflammatory bowel disorder of global importance. In this study, 
a possible route of infection was assessed, i.e. smear-ripened cheese from raw milk. 
Even with a bacteriocin producing starter culture, this study indicates that the 
bacterium would survive manufacture and ripening. Interestingly, lacticin 3147 did 
not impair the normal cheese flora and therefore could be employed in future trials, 
with RT-PCR-based detection, using a MAP inoculum more reflective of normal 
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contamination. However, it is clear from this study that raw milk from animals 
shedding high numbers of MAP cells should not be used for the manufacture of 
smear type cheese. 
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2.8 Tables and Figures 
Table 2.1 Strains used in this study 
 
Strains Characteristic Reference/Source 
   
L. lactis DPC3147 Natural lacticin 3147 producing starter culture Ryan  et al. (1996) 
L. lactis DPC5399 Bac-  Isogenic strain of DPC3147 starter culture DPC Culture Collection 
L.lactis HP Lacticin 3147 sensitive indicator DPC Culture Collection 
L.lactis HP pMRC01 Lacticin 3147 resistant indicator DPC Culture Collection 
MAP ATCC19698 Target organism ATCC 
   
DPC: Dairy Products Research Centre, ATCC: American Type Culture Collection  
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Table 2.2 Oligonucleotides used in this study 
 
Oligonucleotide  
Target 
gene 
Sequence 
Reference 
    
L1 IS900 5'-CTTTCTTGAAGGGTGTTCGG-3'  
 
(Bull et al., 
2003) 
L2 IS900 5'-ACGTGACCTCGCCTCCAT-3' 
AV1 IS900 5'-ATGTGGTGGCTGTGTTGGATGG-3' 
AV2 IS900 5'-CCGCCGCAATCAACTCCAG-3' 
    
IS900QFForward IS900 5'-CCGGTAAGGCCGACCATTA-3'  
(Rodriguez-
Lazaro et 
al., 2005) 
IS900QR Reverse IS900 5'-ACCCGCTGCGAGAGCA-3' 
IS900QP Probe IS900 5'-FAM-CATGGTTATTAACGACGACGCGCAGC–TAMR -3' 
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Table 2.3 Raw Milk Analysis 
 
Analysis Cheese Trail 1 Cheese Trial 2 
   
Total bacterial count  9.9 x 10
3 cfu /ml 4.4 x 103 cfu/ml 
Somatic cell count 3.4 x 10
5 cfu/ml 2.8 x 105 cfu/ml 
% Fat 4.53 4.30 
% Lactose 4.46 4.71 
% Protein 3.16 3.24 
Antibiotic residues Absent Absent 
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Table 2.4 RT-PCR Results 
 
Sample Reference Ct Value 
  
Trail 1 Day 0 Control 18.0000 
Trail 1 Day 0 Lacticin 3147 Producer 17.4656 
Trail 1 Week 1 Control 17.2108 
Trail 1 Week 1 Lacticin 3147 Producer 16.9647 
Trail 1 Week 2 Control 16.9362 
Trail 1 Week 2 Lacticin 3147 Producer 16.6056 
Trail 1 Week 3 Control 17.1505 
Trail 1 Week 3 Lacticin 3147 Producer 16.5786 
Trail 1 Week 4 Control 17.5554 
Trail 1 Week 4 Lacticin 3147 Producer 17.3316 
Trail 2 Day 0 Control 17.2042 
Trail 2 Day 0 Lacticin 3147 Producer 18.0386 
Trail 2 Week 1 Control 16.2401 
Trail 2 Week 1 Lacticin 3147 Producer 16.4913 
Trail 2 Week 2 Control 16.1759 
Trail 2 Week 2 Lacticin 3147 Producer 16.5469 
Trail 2 Week 3 Control 15.9728 
Trail 2 Week 3 Lacticin 3147 Producer 16.1388 
Trail 2 Week 4 Control 19.6297 
Trail 2 Week 4 Lacticin 3147 Producer 16.3408 
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Figure 2.1 Production of the smear on the surface of the cheese 
                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The growth of the smear from appliance (panel A.) and its growth over the ripening period of the 
cheese; panel B. after 1 week, panel C. after 2 weeks, panel D. after 3 weeks and panel E. after 4 
weeks. 
 
 
 
 
 
A. 
B. 
C. 
D. 
E. 
68 
 
Figure 2.2 % Moisture during ripening period 
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Figure 2.3 pH change during ripening period 
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Figure 2.4 MAP enumerations over 28 day ripening period 
 
 
Survival of MAP ATCC19698 in a raw milk smear ripened cheeses in the presence and absence of a 
lacticin 3147-producing starter culture. CPC - Cetylpyridinium chloride 
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Chapter III 
 
Intensive mutagenesis of the Nisin hinge leads to the 
rational design of enhanced derivatives 
 
Brian Healy, Des Field, Paula M O’Connor, Colin Hill, Paul D. Cotter and R. Paul 
Ross 
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3.1 Abstract 
 
Nisin A is the most extensively studied lantibiotic and has been used as a 
preservative by the food industry since 1953. This 34 amino acid peptide contains 
three dehydrated amino acids and five thioether rings. These rings, resulting from 
one lanthionine and four methyllanthionine bridges, confer the peptide with its 
unique structure. Nisin A has two mechanisms of action, with the N-terminal domain 
of the peptide inhibiting cell wall synthesis through lipid II binding and the C-
terminal domain responsible for pore-formation. The focus of this study is the three 
amino acid ‘hinge’ region (N 20, M 21 and K 22) which separates these two domains 
and allows for conformational flexibility. 
As all lantibiotics are gene encoded, novel variants can be generated through 
manipulation of the corresponding gene. A number of derivatives in which the hinge 
region was altered have previously been shown to possess enhanced antimicrobial 
activity. Here we take this approach further by employing simultaneous, 
indiscriminate site-saturation mutagenesis of all three hinge residues to create a 
novel bank of nisin derivative producers. Screening of this bank revealed that 
producers of peptides with hinge regions consisting of AAK, NAI and SLS displayed 
enhanced bioactivity against a variety of targets. These and other results suggested a 
preference for small, chiral amino acids within the hinge region, leading to the 
design and creation of producers of peptides with hinges consisting of AAA and 
SAA. These producers, and the corresponding peptides, exhibited enhanced 
bioactivity against Lactococcus lactis HP, Streptococcus agalactiae ATCC 13813, 
Mycobacterium smegmatis MC2155 and Staphylococcus aureus RF122 and thus 
represent the first example of nisin derivatives that possess enhanced activity as a 
consequence of rational design.  
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3.2 Introduction 
 
Bacteriocins are small, bacterially produced, ribosomally synthesized 
peptides that are active against other bacteria and against which the producer has a 
specific immunity mechanism (Cotter et al., 2005, Cotter et al., 2013). The 
bacteriocins can be subdivided on the basis of their structure with Class 1 consisting 
of peptides that have undergone post-translational modification (Rea et al., 2011). Of 
these, the lantibiotics have been the focus of particular attention (Chatterjee, 2005, 
Bierbaum & Sahl, 2009). The name of these bacteriocins reflects their structure; 
‘Lanthionine-containing antibiotics’, where lanthionines/ -methyllanthionines are 
unusual residues that are formed between cysteines and neighbouring dehydrated 
serines (dehydroalanines) or threonines (dehydrobutyrines), respectively (Bierbaum 
& Sahl, 2009).   
The lantibiotic Nisin A (Fig. 3.1) has been used a commercial food additive 
since 1953 and has been approved for use in food by the FAO, WHO, EU and the 
USFDA (Delves-Broughton et al., 1996, Cotter et al., 2005). Unsurprisingly, Nisin 
A is by far the most extensively studied lantibiotic (Delves-Broughton et al., 1996, 
Cotter et al., 2005, Lubelski et al., 2008). In addition, the gene encoded nature of 
nisin, and indeed other lantibiotics, can be exploited through engineering to even 
further enhance its activity and/ or investigate structure-function relationships. Such 
engineering can be carried out in vivo (manipulation of the producer or heterologous 
expression of the genes in another host) or in vitro (using purified components of the 
biosynthetic machinery) (Rink et al., 2005, Field et al., 2008, Healy et al., 2010, 
Knerr & van der Donk, 2012). 
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 The in vivo engineering of nisin through the replacement of specific amino 
acids commenced in 1992 (Kuipers et al., 1992) and a number of derivatives were 
identified that have been of considerable value with respect to revealing the 
fundamentals of nisin biology (Cotter et al., 2005, Field et al., 2010). More recently, 
derivatives have been identified with academic and potential commercial value that 
display enhanced activity against pathogenic bacteria (Yuan et al., 2004, Field et al., 
2008, Field et al., 2012, Molloy et al., 2012, Rouse et al., 2012, Molloy et al., 2013). 
The majority of these enhanced derivatives differ with respect to the amino acids 
found in the 3 amino acid ‘hinge’ region of the peptide. This region is thought to be 
key with respect to linking the two functional domains of the nisin peptide and 
providing conformational flexibility between these regions (Breukink et al., 1997, 
Wiedemann et al., 2001). Nisin inhibits cell wall synthesis through the formation of 
a complex with lipid II, an essential precursor of peptidoglycan synthesis (Brotz et 
al., 1998, Breukink et al., 1999), with the N-terminus region being responsible for 
this binding (Hsu et al., 2004). The hinge links this domain with the C-terminal end 
of the peptide, which is responsible for a second mechanism of antimicrobial 
activity, which involves permeabilisation of the cell membrane. The first indication 
that mutagenesis of the hinge could bring about beneficial consequences was 
provided by Yuan and co-workers (2004) who established that two derivatives of 
nisin Z (N20K and M21K), exhibited enhanced activity against Gram-negative 
(Shigella, Pseudomonas and Salmonella), but not Gram-positive, pathogens. This 
was followed by the identification of hinge derivatives, such as N20P, M21V, K22S 
and K22T (Field et al., 2008), with enhanced activity against Gram-positive 
pathogens (Streptococcus agalactiae, Staphylococcus aureus and Listeria 
monocytogenes). Further studies have emphasised the enhanced potency of one of 
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these variants, nisin V (M21V) (Field et al., 2010), against a broad variety of drug-
resistant pathogens and have identified other hinge derivatives, such as that 
containing the residues SVA, that exhibit enhanced activity in complex matrices 
(Rouse et al., 2012). 
The hinge derivatives that have been studied to date have resulted from 
strategies in which one or two of the hinge residues have been manipulated. Here we 
go a step further through the randomisation of all three hinge residues 
simultaneously. Screening of a bank of producers of such derivatives revealed a 
pattern whereby many producers of derivatives containing small chiral amino acids 
within the hinge displayed enhanced bioactivity. This prompted the rational design 
of additional derivatives not identified from the random bank, peptides containing 
AAA and SAA hinges, which were particularly notable with respect to the extent to 
which bioactivity was enhanced, relative to the wild-type producer.   
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3.3 Materials and Methods 
 
3.3.1 Bacterial strains and growth conditions  
 
All strains and plasmids used in this study are listed in Table 3.1 Lactococcus lactis 
cultures were grown in M17 broth or agar (1.5%) (Oxoid) supplemented with 0.5% 
glucose at 30˚C. Escherichia coli strains were grown in Luria-Bertani (LB) broth or 
agar with continuous shaking at 37˚C. Where necessary, chloramphenicol was used 
at 10 μg/ml for L. lactis and E. coli. Staphylococcus aureus RF122 was grown in 
Brain Heart Infusion (BHI) broth or agar (Oxoid) at 37˚C. Streptococcus agalactiae 
ATCC 13813 was grown in Tryptic Soy Broth (TSB) (Merck) or TS agar 
supplemented with Yeast Extract (YE) (Oxoid) at a concentration of 0.6% at 37˚C.  
Mycobacterium smegmatis MC2155 was grown on Middlebrook 7H9 broth (BD) or 
Middlebrook 7H10 agar (BD) supplemented with 0.05% tween 80 and 2% glycerol 
at 37˚C. 
3.3.2 Site-saturation mutagenesis of the nisin A ‘hinge’ region 
 
The complete randomisation of the ‘hinge’ amino acids was achieved by PCR using 
the template pDF05 (pCI372–nisA) and primers NisAXXXHingeFor and 
NisAXXXHingeRev (Table 3.2). The template DNA was extracted using a High 
Pure Plasmid Isolation Kit (Roche) from dam
+
 E. coli Top10 (Invitrogen) to ensure 
its methylation. PCR amplification was performed in 50µl volumes with 1 ng per 50 
µl of template, 2 units of Phusion High Fidelity DNA Polymerase (Finnzymes), 
approximately 0.5 ng of template, 1x HF buffer, 200 µM dNTPs and 0.5 µM of the 
relevant oligonucleotides. Cycling conditions were as follows: 98˚C for 30 secs, 
55˚C for 15 secs, 72˚C for 3.5 mins for 40 cycles followed by final extension for 10 
mins. Samples were PCR cleaned using GeneJet PCR Purification Kit (Thermo 
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Scientific) followed by DpnI treatment (Stratagene) at 37˚C for 3 hours. 2.5 µl of 
mutated pCI372-NisA was added to a vial of Top 10 Chemically Competent 
Escherichia coli (Invitrogen). These transformants were pooled, plasmids extracted 
using a High Pure Plasmid Isolation Kit (Roche) and transformed into electro-
competent L. lactis ssp. cremoris NZ9800∆nisA and selected for on GM17 Cm10 agar 
within Q-Trays. Resultant colonies were picked and added to GM17 within Genetix 
96-well plates (Genetix X6011), incubated overnight at 30°C before storage at -80˚C 
in 44% glycerol (Sigma). 
3.3.3 Site-directed mutagenesis of the nisin A ‘hinge’ region 
 
The creation of targeted changes was also facilitated using a PCR-based approach, 
using oligonucleotides (Table 3.2) and a suitable pDF05 based template (one which 
most closely resembles the desired change). Amplification was through a 50µl PCR 
reaction containing 0.02U/µl KOD Hot-Start Polymerase (Novagen), 1.5 mM 
MgSO4, 0.2 mM of each dNTP, 0.3 µM of both oligonucleotides and approximately 
10 ng of template. Cycling conditions were as described above. Engineered plasmids 
were introduced into L. lactis NZ9800∆nisA via E. coli Top10 as described above. 
3.3.4 Deferred antagonism assays 
 
Deferred antagonism agar-based assays were employed to assess the bioactivity of 
nisin derivative-producing strains (Rouse et al., 2012). Briefly, the L. lactis 
producers were ‘spotted’ (approximately 3 µl) onto GM17 agar and incubated for 16 
hours at 30˚C. In the case of M. smegmatis, the L. lactis producers were incubated 
for 40 hours. Growth media (0.75% agar) appropriate for growth of the individual 
target was seeded (0.5%) and poured over the L. lactis producers followed by further 
incubation at conditions suitable for the indicator. Enhancement in bioactivity was 
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indicated by increased zone of inhibition relative to that generated by the wild-type 
producer. 
3.3.5 Agar well diffusion assays 
 
50 µl volumes of purified peptide were added to wells bored in the appropriate agar-
containing media (1.5% agar, 0.75% for M. smegmatis) seeded with 0.5% of a 16 
hour culture (40 hour culture for M. smegmatis) of the indicator of interest. Plates 
were incubated for 16 hours (40 hours for M. smegmatis) and bioactivity assessed on 
the basis of the size of the zone of inhibition.  
3.3.6 Identification of nisin A derivatives  
 
Colony mass spectrometric analysis was carried out on colonies exhibiting enhanced 
bioactivity using an Axima CFR plus MALDI TOF mass spectrometer (Shimadzu 
Biotech, Manchester, UK) and analyzed in positive-ion reflectron mode as 
previously described (Field et al., 2008). The changes to the nisA genes within the 
corresponding pDF05 derivatives were established through DNA sequencing 
(MWG, Biotech, Germany). The sequences for AAA, AAK, NAI, SAA and SLS 
were deposited in GenBank under the accession numbers KF664587, KF664588, 
KF664589, KF664590 and KF664591, respectively.   
3.3.7 Purification of nisin A and derivatives thereof 
 
2 litres of Tryptone Yeast (TY) broth were incubated for 20 hours with 20 ml of an 
overnight culture of producing strain. This culture was centrifuged for 20 minutes @ 
8630g. The supernatant was decanted and passed through 60g of pre equilibrated 
Amberlite XAD16 beads (Sigma-Aldrich). The beads were washed with 500ml 30% 
ethanol and eluted with 500 ml 70% isopropanol (IPA) (Fisher) 0.1% trifluoroacetic 
acid (TFA) (Sigma-Aldrich). Concomitantly, the cell pellets were resuspended in 
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300 ml of 70% IPA 0.1% TFA and stirred at room temperature for 3 hours followed 
by centrifugation. This cell supernatant was combined with that referred to above 
and concentrated through rotary-evaporation (Buchi, Switzerland) to approximately 
250ml. After the pH was adjusted to 4.5 further concentration was achieved through 
the use of a Phenomenex SPE C-18 column to a final volume of 60 ml. 7 ml of this 
sample was concentrated, through rotary evaporation, to 2 ml and purified through 
HPLC using a Phenomenex C12 Reverse-Phase (RP) HPLC column (Jupiter 4 µ 
proteo 90 Å, 250 X 10.0 mm, 4 µm). To facilitate this, a gradient of 30-50% 
acetonitrile (Fisher) containing 0.1% TFA was developed. The relevant fractions 
were collected and pooled, subjected to rotary-evaporation to remove acetonitrile 
and freeze-dried (LABCONCO). The purified peptides were subjected to MALDI-
ToF Mass Spectrometric analysis to confirm their purity before use. 
3.3.8 Minimum Inhibitory Concentration (MIC) Assays 
 
Minimum inhibitory concentration assays were carried out in triplicate using 96-well 
plates (Sarstedt) pretreated with bovine serum albumin (BSA) as previously 
described (Wiedemann et al., 2006). Wild-type nisin A and nisin derivatives were 
adjusted to a 500 nM (when using L. lactis as a target) or 7.5 µM (all other 
indicators) starting concentration and 2-fold serial dilutions of each peptide were 
carried out. An overnight of the target strain was subcultured and incubated to an 
OD600nm of 0.5 before being diluted to give a final inoculum of 10
5 
cfu/ml in 200 
μl. The plates were incubated at an appropriate temperature and inspected after 16 
hours. The MIC was determined as the lowest concentration at which no growth was 
visible. 
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3.4 Results 
3.4.1 Creation of a bank of producers of randomised hinge 
derivative 
 
In order to fully exploit the potential of the nisin ‘hinge’ region (N20-M21-K22) to 
generate enhanced derivatives, it was decided to undertake a complete randomisation 
of this area. Using NNK scanning of the nisin A structural gene (nisA), a large bank 
of L. lactis NZ9800 pCI372nisA (pDF05) hinge variants were produced. In order to 
obtain full coverage with a 95% confidence limit using NNK scanning on three 
positions, a bank of 341,601 variants would have to be screened (Nov, 2012). 
Creating and screening a bank of this size against four indicators would not have 
been feasible and thus a more practical bank of 12,000 variants was produced in 
order to increase the likelihood of finding interesting candidates in a short/ medium 
time frame. 
3.4.2 Identification of nisin derivative producers with enhanced 
bioactivity 
 
The bank of producers of randomised hinge derivatives was screened using deferred 
antagonism agar diffusion assays to identify producers that display enhanced 
bioactivity. The term bioactivity, as used here and elsewhere (Field et al., 2008, 
Rouse et al., 2012, Molloy et al., 2013), reflects the overall activity of producer 
strains and does not discriminate between effects due to increased/ decreased 
specific activity, altered peptide production levels, or effects on other physico-
chemical properties such as diffusion in agar. Enhanced bioactivity was 
characterised by zones of clearing greater than that generated by the corresponding 
nisin A producing control against Lactococcus lactis HP, Streptococcus agalactiae 
ATCC 13813, Mycobacterium smegmatis MC2155 or Staphylococcus aureus 
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RF122. From this screen 63 potentially enhanced producers were selected for further 
investigation and, after DNA sequencing, it was established that these corresponded 
to 23 unique mutants (Table 3.3). These 23 derivatives contained hinge regions 
consisting of combinations of 12 distinct amino acids (Table 3.4), none of which 
were aromatic or negatively charged in nature. Of these 12, alanine was most 
common (22%), followed by serine (16%) and glutamine (12%). To exclude that a 
bias or over-presentation of specific residues had occurred, and to insure the overall 
randomisation of the bank, 20 clones were chosen randomly and their hinge region 
was sequenced. The results are presented in Table 3.5 and establish that alanine and 
serine are not considerably over-represented within the bank. From the agar diffusion 
assays it was apparent that three producers consistently produced large zones of 
inhibition and these were selected for further investigation. DNA sequencing and 
mass spectrometric analysis revealed that the derivatives produced by these strains 
contained hinge regions consisting of AAK, SLS and NAI (Table 3.6). Assays with 
four target microorganisms established that the producer of the AAK-containing 
derivative exhibited enhanced bioactivity against L. lactis HP, S. aureus RF122 and 
M. smegmatis MC2155, the producer of the SLS-containing derivative exhibited 
enhanced bioactivity against L. lactis HP and M. smegmatis MC2155 and the 
producer of the NAI-containing derivative exhibited enhanced bioactivity against L. 
lactis HP, S. agalactiae ATCC 13813 and M. smegmatis MC2155. This 
enhancement could potentially be as a result of enhanced production, enhanced 
specific activity or some other enhancement with respect to the attributes of the 
peptide. To investigate these various possibilities, the three peptides produced by 
these strains (and wild-type nisin A) were purified through HPLC and broth-based 
specific activity and agar diffusion assays were performed (Table 3.7). Against L. 
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lactis HP, all three bioengineered peptides displayed enhanced activity, relative to 
equal concentrations of nisin A, when assessed through agar diffusion assays. 
However, this was not due to enhanced specific activity as broth-based MIC assays 
revealed that the activity of the NAI-containing peptide was equal, and those of the 
AAK- and SLS-containing peptides were reduced, relative to that of nisin A against 
this target (Table 3.7). All of the nisin derivatives displayed specific activity in broth 
which was reduced relative that of the wild-type peptide against S. aureus RF122, 
yet the AAK- and NAI-containing peptides exhibited enhanced activity when 
assessed through agar diffusion assays, with the enhanced activity of the AAK-
containing peptide being most significant (Table 3.7). When tested against S. 
agalactiae ATCC 13813, the NAI-containing peptide displayed significantly 
enhanced activity against this target in agar diffusion assays and in broth based 
specific activity assays. Regardless of assay, neither the AAK- nor the SLS-
containing peptides exhibited enhanced activity against S. agalactiae ATCC 13813 
(Table 3.7). M. smegmatis MC2155 was also included as an indicator as M. 
smegmatis is frequently used as a model microorganism/ substitute for slow-
growing, pathogenic mycobacteria. The AAK-containing peptide and the SLS-
containing peptides both showed significant enhanced activity against this target in 
agar diffusion assays (Table 3.7), but the aggregative nature of MC2155 in broth 
precluded the generation of consistent MIC data from broth-based studies.  
3.4.3 Rational design of nisin derivatives with enhanced bioactivity 
 
The amino acid composition of nisin hinges within strains exhibiting enhanced 
bioactivity revealed some trends. All ‘improved’ hinge regions had a mass less than 
that of the wild-type, alanines were frequently identified at each position and, on a 
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number of occasions, multiple alanines were present. Based on these observations, it 
was postulated that a nisin derivative with a hinge consisting of AAA could 
potentially display enhanced properties. The presence of a serine, particularly at 
position 20, in the nisin hinge of other strains displaying enhanced bioactivity has 
also been noted, including hinges consisting of SMT and SLS from this study and 
SVA from Rouse et al. (2012). On the basis of this observation, a nisin derivative 
containing a SAA hinge was also created. To further test the theory that nisin 
derivatives with a hinge consisting of small amino acids may exhibit enhanced 
features, site-directed mutagenesis was also used to create a hinge derivative 
consisting of glycine residues only. In this last case, the producer of the GGG-
containing hinge did not exhibit antimicrobial activity. It would thus seem that a lack 
of chirality within the hinge is a negative feature. 
 In contrast, the respective producers of the AAA- and SAA-containing peptides 
displayed enhanced bioactivity against each of the four strains tested and again were 
purified for specific activity assays (Tables 3.6 and 3.7). Both the AAA- and SAA-
containing peptides showed significantly enhanced specific activity relative to nisin 
A against all four indicators in agar diffusion assays. In each case, this enhancement 
was more significant in the case of the AAA-containing peptide. In contrast, in broth 
based specific activity assays the bioengineered peptides exhibited activity that was 
equal or reduced relative to that of the wild-type peptide, with the exception that the 
AAA-containing peptide showed a two-fold improvement relative to the natural 
peptide against S. agalactiae ATCC 13813. Thus, while in many cases it would 
appear that enhanced bioactivity is attributable to enhanced diffusion through 
complex media, a phenomenon previously reported by Rouse  et al. (2012), this 
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result establishes that antimicrobial potency can also be a contributory factor with 
respect to some targets. 
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3.5 Discussion 
 
In this study a large bank of derivatives of the lantibiotic nisin was generated 
in which all three hinge residues were simultaneously randomised. To facilitate the 
relatively rapid screening of such a large number of derivative-producing strains, the 
deferred antagonism assay was employed. This approach allows for the identification 
of variants with enhanced bioactivity and can be supported by further assays to 
determine if this enhanced bioactivity is attributable to enhanced specific activity 
(Field et al., 2010, Field et al., 2012) production and/ or solubility /diffusion (Rouse 
et al., 2012). Regardless of the specific underlying basis for the enhanced bioactivity 
of a particular derivative, any enhanced feature has the potential to be exploited in 
food or medicine. This is especially true when one considers the number of 
applications which are available to lantibiotics, and nisin in particular (Cotter et al., 
2005).  
Preliminary screening of this bank resulted in the identification of 23 
derivative producers with enhanced bioactivity. Of these 23, producers of nisin 
derivatives containing SLS, AAK or NAI within the hinge region were brought 
forward for further characterisation. In the case of the SLS-containing example, the 
selection of a strain producing nisin with a serine (S) at positions 20 and 22 was 
consistent with observations made by Field et al. (2008) and Rouse et al. (2012), 
who previously established that the introduction of this hydrophilic amino acid at 
position 22 and 20 can result in enhanced bioactivity. Field and co-workers have also 
previously noted that the introduction of a leucine (L) at position 21, in several 
instances, lead to relatively high levels of activity. With respect to the NAI-
containing derivative, nisin A naturally contains an asparagine (N) at position 20, the 
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benefits of incorporating alanines will be discussed in greater depth below and, 
although there is no precedent for an enhanced derivative containing an isoleucine (I) 
at position 22, its introduction at the other two hinge positions has had varying 
effects on bioactivity (Field et al., 2008). The introduction of alanines in the AAK-
containing peptide will be discussed below. 
Although this is not the first study which has fully randomised the nisin 
‘hinge’ region, it is the first to do so in the context of the full length nisin peptide. 
Previously, Plat and co-workers (2011) randomised all three positions in a truncated 
form of nisin, i.e. nisin-(1-22), and found when they analysed 16 of the active 
derivatives that the size of the zone was directly, for the most part, proportional to 
the amount of the prepeptide produced. However, in that instance the derivatives that 
exhibited the largest zones of activity both contained the aromatic amino acid 
tryptophan (W); AWR and WRA. In contrast, in this study none of the peptides 
produced by the ‘hinge’ mutants that displayed enhanced bioactivity contained 
aromatic amino acids. The differences between the composition of the hinges in 
enhanced peptides from these respective studies suggest that the hinge is performing 
a different role in the truncated, relative to the intact, peptide and that in the latter 
instance the impact on the hinge residues on the C-terminal domain is critical. 
Despite these differences, it is apparent that there is a consistent absence of 
negatively charged amino acids from within the hinge of all peptides and strains 
exhibiting enhanced bioactivity. This is also consistent with the previous studies of 
Field et al. (2008) and Yuan et al. (2004). 
 Well diffusion assays using purified forms of the SLS-, AAK- and NAI-
containing peptides established that enhanced bioactivity was attributable to an 
enhanced diffusion in agar in a manner similar to that previously reported by Rouse 
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et al. (2012). This trait was previously noted as being a valuable one in that such a 
peptide performed better than wild-type nisin A with respect to controlling Listeria 
monocytogenes in a food system. The identity of these, and other, changes that 
occurred in the hinge region of peptides associated with enhanced bioactivity in the 
preliminary screening also provided a further insight into the flexibility of the hinge 
and revealed distinct patterns (Tables 3.3 and 3.4). The frequency with which alanine 
appears was particularly notable. Among the strains that exhibited enhanced 
bioactivity, alanine was the amino acid that was most frequently located at positions 
20 (30%) and 21 (22%) and was also frequently identified at position 22 (13%). It 
was also noted that a pair of alanines was located in the hinge region of peptides 
from three strains exhibiting enhanced bioactivity. The AAK-containing peptide is a 
perfect example of this pattern. The third residue, lysine, is conserved across all 
natural variants of nisin; nisin A (Kaletta & Entian, 1989), nisin Z (Mulders et al., 
1991), nisin Q (Zendo et al., 2003), nisin F (de Kwaadsteniet, et al., 2008), nisin U 
and U2 (Wirawan et al., 2006) and most recently nisin P (Zhang et al., 2012). The 
enhanced bioactivity of the corresponding strain and the specific activity in agar of 
the corresponding peptide was particularly apparent against S. aureus RF122 (Tables 
3.6 and 3.7). Despite the conserved nature of this lysine, this study and others (Field 
et al., 2008, Rouse et al., 2012) have demonstrated that this residue can be changed. 
On the basis of these observations it was decided to bioengineer a strain to produce a 
peptide in which the ‘hinge’ would consist wholly of alanines. The fact that these 
changes enhanced the bioactivity of the associated strain means that this is the first 
instance upon which a characteristic of nisin has been enhanced through rational 
design. The additional hinge derivative to result from rational design contained a 
hinge consisting of SAA. The creation of this peptide was targeted due to the 
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previous observation that enhanced bioactivity was evident in strains that produced 
peptides with a serine at position 20 of the nisin peptide, including SMT, SLS and 
SVA (Rouse et al., 2012). The bioactivity of the resultant strain (Table 3.6) was also 
greater than that of nisin wild-type producer against all indicators tested. The fact 
that the newly introduced serine remained unmodified is in agreement with 
observations made previously by Lubelski (2009), where it was suggested that 
serines in positions immediately preceding lanthionine bridges remain unmodified. 
The fact that the addition of small chiral amino acids to the hinge resulted in an 
increase in bioactivity may be attributable to an increase in ‘hinge’ flexibility. In 
contrast, the production of the achiral glycine ‘hinge’ may confer a structurally weak 
hyper flexible ‘hinge’ lacking in any distinguishable conformity through mis-
folding. It should also be noted that, while we focused on the observation that 
alanine and serine were frequently identified across all hinge residues in strains with 
enhanced bioactivity, there may be merit in designing residues whereby the amino 
acid at each respective location is optimised. Indeed, the positively charged histidine 
was found very frequently at position 20 in these strains while, at position 21, the 
hydrophobic residues valine, leucine and isoleucine are very prominent. The identity 
of the residues located at position 22 was more variable.  
Ultimately, the ‘hinge’ region of nisin has again been established to be a 
worthy target with respect to bioengineering to enhance bioactivity. The benefits of 
incorporating small chiral amino acids were particularly apparent leading to, for the 
first time, the rational design of nisin ‘hinge’ derivatives with enhanced properties. 
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3.8 Tables and Figures 
Table 3.1 Plasmids & strains used in used in this study 
 
Plasmid/Strains Characteristic Reference/Source 
   
pDF05 pCI372 with  nisA Field et al.(2008) 
pDF05 AAK pDF05 with N20A/M21A substitution in nisA This study 
pDF05 AAA pDF05 AAK with K22A substitution in nisA AAK This study 
L. lactis NZ9800 L. lactis NZ9700 ΔnisA Rea et al. (2011) 
L. lactis NZ9800 pDF05 Wild-type nisin A producer Field et al. (2008) 
E. coli Top10 Intermediate cloning host Invitrogen 
M. smegmatis MC2155 
Model microorganism for slow-growing  
ATCC  
mycobacteria species 
S. agalactiae ATCC 13813 Indicator strain ATCC 
L. lactis ssp cremoris HP Indicator strain UCC Culture Collection 
S. aureus RF122 Bovine mastitis-causing isolate Herron-Olson et al. (2007) 
   
ATCC: American Type Culture Collection, UCC: University College Cork 
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Table 3.2 Oligonucleotides used in this study. 
 
Oligonucleotide  Sequence 
  
NisAXXXHingeFor 5'- PHO TGATGGGTTGTNNKNNKNNKACAGCAACTTGTCATTGTAGT -3' 
NisAXXXHingeRev 5'-  CAAGTTGCTGTMNNMNNMNNACAACCCATCAGAGCTCCTGT -3' 
pCI372Rev 5'- ACCTCTCGGTTATGAGTTAG -3' 
For Primer (AAA) 5'- GTTGTGCTGCGGCAACAGCAACTTGTCATTGTAGTATTCAC -3' 
Rev Primer (AAA) 5'- CAAGTTGCTGTTGCCGCAGCACAACCCATCAGAGCTCCTGT -3' 
AAA Check Primer For 5'- CTGATGGCTTGTGCTGCGGCA -3' 
SAA HC For 5'- TGATGGGTTGTTCAGCGGCTACAGCAACTTGTCATTGTAGT -3' 
SAA HC Rev 5'- GCTGTAGCCGCTGAACAACCCATCAGAGCTCCTGTTTTACA -3' 
SAA Forward SLT Codon 5'- TGATGGGTTGTTCGGCGGCTACAGCAACTTGTCATTGTAGT -3' 
SAA Reverse SLT Codon 5'- GCTGTAGCCGCCGAACAACCCATCAGAGCTCCTGTTTTACA -3' 
GGG Forward Primer 5’ GATGGGTTGTGGAGGTGGAACAGCAACTTGTCATTGTAGTA ‘3 
GGG Reverse Primer 5’ AGTTGCTGTTCCACCTCCACAACCCATCAGAGCTCCTGTTT ‘3 
GGG Check Primer 5’ TCTGATGGGTTGTGGAGGTGGA ‘3 
  
 
PHO – 5’- Phosphate modification. Emboldened – Degenerate codons, emboldened & underlined – 
locations for site-directed mutagenesis 
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Table 3.3 Nisin A ‘hinge’ variants with enhanced bioactivity identified through the 
initial screen.  
 
Variant 
Molecular 
Mass 
Variant 
Molecular 
Mass 
    
HVS 3304 AIT 3266 
MAQ 3311 QVQ 3336 
ASS 3226 SMT 3300 
PVN 3291 HSQ 3332 
ASV 3238 HAA 3260 
HLA 3301 SIN 3294 
NAI 3279 PQK 3334 
ANP 3263 AQV 3278 
SLS 3268 HSQ 3332 
AAI 3236 PNA 3262 
AAK 3250 NQV 3321 
    HLS 3308 
    
 
The three letter code corresponds to the amino acids located at each of the three ‘hinge’ sites. 
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Table 3.4 Frequency with which amino acids are located at each hinge site among 
the derivatives presented in Table 3.3.  
 
Position 20 
(% frequency) 
Position 21 
(% frequency) 
Position 22 
(% frequency) 
   
Alanine  7 (30.4) Alanine 5 (21.7) Serine 4 (17.4) 
Histidine 6  (26.1) Serine 4 (17.4) Glutamine 4 (17.4) 
Proline 3 (13.0) Valine 3 (13.0) Alanine 3 (13.0) 
Serine 3 (13.0) Leucine 3 (13.0) Valine 3 (13.0) 
Asparagine 2 (8.7) Glutamine 3 (13.0) Isoleucine 2 (8.7) 
Glutamine 1 (4.3) Asparagine 2 (8.7) Asparagine 2 (8.7) 
Methionine 1 (4.3) Isoleucine 2 (8.7) Lysine 2 (8.7) 
 Methionine 1 (4.3) Threonine 2 (8.7) 
  Proline 1  (4.3) 
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Table 3.5 Actual and expected frequencies of hinge amino acids from randomly 
selected representatives of the hinge mutant bank 
 
Amino  
Acid Residue 
Actual 
Frequency 
(%) 
Expected 
Frequency 
(%) 
   
Serine 8.33 9.38 
Alanine 6.67 6.25 
Asparagine 6.67 3.13 
Lysine 6.67 3.13 
Tyrosine 6.67 3.13 
Arginine 5.00 9.38 
Glutamine 5.00 3.13 
Glycine 5.00 6.25 
Histodine 5.00 3.13 
Isoleucine 5.00 3.13 
Methionine 5.00 3.13 
Stop 5.00 3.13 
Valine 5.00 6.25 
Aspartic Acid 3.33 3.13 
Cytosine 3.33 3.13 
Glutamic Acid 3.33 3.13 
Leucine 3.33 9.38 
Proline 3.33 6.25 
Threonine 3.33 6.25 
Trytophan 3.33 3.13 
Phenylalanine 1.67 3.13 
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Table 3.6 Deferred Antagonism Results 
 
 
 
 
 
 
 
 
 
 
 
 
The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the 
‘spot’ in mm2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Deferred Antagonism  
  
Zone Area 
(mm
2
) 
p-
value 
Relative to 
WT (%) 
     
L. lactis HP WT 299.58 ± 7.04   
 AAA 492.83 ± 40.27 0.012 164.51 
 AAK 408.89 ± 18.72 0.005 136.49 
 SAA 483.14 ± 33.89 0.009 161.28 
 SLS 370.75 ± 28.28 0.042 123.76 
 NAI 439.52 ± 47.88 0.034 146.71 
S. aureus RF122 WT 138.31 ± 3.36   
 AAA 292.24 ± 11.46 0.001 211.29 
 AAK 292.44 ± 10.36 0.001 211.43 
 SAA 236.28 ± 13.53 0.004 170.83 
 SLS 153.93 ± 7.15 0.045 111.29 
 NAI 16.3.23 ± 10.95 0.049 118.02 
S. agalactiae ATCC 13813 WT 226.55 ± 2.96   
 AAA 401.32 ± 15.62 0.002 177.14 
 AAK 232.00 ± 21.58 0.706 102.41 
 SAA 407.98 ± 18.452 0.003 180.08 
 SLS 209.45 ± 17.11 0.223 92.45 
 NAI 318.81 ± 7.915 0.034 140.72 
M. smegmatis MC2155 WT 51.31 ± 10.08   
 AAA 277.65 ± 60.42 0.02 541.09 
 AAK 199.47 ± 32.36 0.009 388.73 
 SAA 303.85 ± 59.93 0.016 592.15 
 SLS 230.31 ± 20.31 0.001 448.84 
 NAI 270.04 ± 58.30 0.02 526.26 
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Table 3.7 Specific Activity Results 
 
MIC: Minimum Inhibitory Concentration ND: Not Determined 
 
 
 
 
 
 
 
 
  100 mg L
-1
  Agar Diffusion MIC 
  
Zone Area 
(mm
2
) p-value 
Relative to 
WT (%) 
Specific 
Activity as 
% of WT 
      
L. lactis HP WT 267.69 ± 9.21    
 AAA 416.00 ± 17.99 0.001 155.41 100 
 AAK 320.08 ± 14.20 0.009 119.57 50 
 SAA 344.76 ± 18.50 0.008 138.71 50 
 SLS 321.93 ± 22.43 0.038 120.26 25 
 NAI 371.32 ± 19.60 0.004 128.79 100 
S. aureus RF122 WT 99.34 ± 12.33    
 AAA 155.77 ± 3.30 0.011 156.81 25 
 AAK 178.23 ± 13.39 0.002 179.42 50 
 SAA 130.60 ± 4.46 0.036 131.47 25 
 SLS 98.82 ± 10.14 0.957 99.47 <6 
 NAI 129.75 ± 11.36 0.035 130.61 25 
S. agalactiae 
ATCC 13813 WT 246.31 ± 2.74    
 AAA 305.58 ± 2.39 0.000 124.06 200 
 AAK 234.55 ± 4.23 0.021 95.23 50 
 SAA 301.62 ± 8.18 0.004 122.46 100 
 SLS 226.05 ± 4.10 0.003 91.78 25 
 NAI 291.52 ± 8.46 0.007 118.36 200 
M. smegmatis 
MC2155 WT 67.79 ± 4.308    
 AAA 149.24 ± 4.776 0.000 220.15 ND 
 AAK 105.73 ± 6.930 0.003 155.96 ND 
 SAA 101.19 ± 11.510 0.026 149.27 ND 
 SLS 119.56 ± 8.59 0.003 176.36 ND 
 NAI 78.50 ± 8.16 0.137 115.8 ND 
      
 100 
 
Figure 3.1 A - Nisin A mature peptide, B - AAA Producer (Deferred Antagonism 
Assay). 
Panel A. Dha – Dehydroalanine; Dhb – Dehydrobutyrine. Hinge region highlighted. Five (-
methyl)lanthionine rings labelled A-E. Arrows denote amino acid changes to produce AAA derivative 
in the nisin hinge region. Panel B. Zones of inhibition produced by L. lactis NZ9800 pDF05(left) and 
AAA ‘hinge’ variant (right) against L. lactis HP. 
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